

ಆಂಧ್ರಪ್ರವೆ हैं आंध्र प्रदेश ANDHRA PRADESH

SL No: 10 262 0 10 20 21 Rs: 207

sold 10 y.v. Apjaneyuly slo sectard maids, Gutur

For Whom

the Institute of Phonograpical Eciene

ot No. 127, Shivlok Complex, IDA Jeedimetla, Phase V (extn.), Doolapally Road, Hyderabad-500 100. T.S. India. Tel: +91-40-2988 3999 || Email: marketing@anigenerics.com || www.anigenerics.com

memorandum of undersanding between Chalapathi institute of pharmaceutical sciences, Guntur

ANIZ

M/S. ANI Generics Private Limited

COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

In accordance with the mutual desire to promote cooperation between the institute CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, Guntur and the Company M/S. ANI Generics Private Limited enter into this formal statement of collaboration in the form of Memorandum of Understanding (M.O.U.) for the purpose of Academic and Professional exchanges.

Both the institutions have found it mutually beneficial to explore co-operative activities for the following purposes.

- Training of B.Pharmacy students every year for a period of one month at ANI Generics Private Limited by assignment of short term Research Projects.
- 2. Collaboration in Research activities between Industry and Institute.
- Exchange of visits between Chalapathi Institute of Pharmaceutical Sciences and ANI Generics Private Limited. Professionals /Faculty Members of the institute to their counter part and place.
- 4. Organization of joint Seminars/Training Programmes/Meetings.
- 5. Placement of B,Pharmacy/M.Pharmacy students whenever it is possible.
- It is understood that the details of joint activities/conditions for the utilization of results achieved, arrangements for specific visits, exchange and all other form of co-operation will be handled on mutually agreeable terms for each specific case.

Dr. Manus Rac Nadendia Principal Chalapathi Inst. of Pharm. Sciences, Lam. Juntur

Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)

Chalapathi Nagar, t A相, GUNTUR-34.

KONDA MOHAN REDDY

LICENCED STAMP VENDOR

D.No: 19-71, TADIKONDA MTUR Dt. Cell: 9866368173

L.No: 07-14-010/2014 R.L. No: 07-14-005/2021



SL No: 10269 Date: 29/10/2021 Rs: 201

KONDA MOHAN REDDY

LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021

D.No. 19-71, TADIKONDA NTHE DE Cell: 9866368173

GUNTHER

sectaramaiah, Gutur Anjaneque For Whom GUNTUR, A.P. MOIA

MEMORANDUM OF UNDERSTANDING / COLLABORATION BETWEEN CHALAPATHI INSTITUTE OF SCIENCES, GUNTUR IN, AND MARKET ACCESS SOLUTIONS LLC (MKTXS), RARITAN, USA.

Objective :

Market Access Solutions LLC (MKTXS), USA assents to establish Memorandum of Understanding / Collaboration for Internship and Placements with Chalapathi Institute of Pharmaceutical Sciences, India.

We, Market Access Solutions LLC (MKTXS) agrees to hereby establish a Memorandum of Understanding with Chalapathi Institute of Pharmaceutical Sciences (CLPT), India - with regard to an internship program, facilitating the organization acceptance of CLPT students as interns and thereafter providing Placements. We hope this co-operation would be a major benefit to the student community to enhance their skills and knowledge in Market Access. We also believe that this internship and exposure provided to the students through this association will build confidence and prepare the students to have a smooth transition from academic to working career. Students should work / inter for Market Access Solutions LLC (MKTXS) for minimum two years.

We plan to visit the campus in the near future and interact with the Management, Faculty and Students. Hope we have a good collaboration.

Prof. RAMARAO NADENDILA

Principal
Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lem, Guntur- 522 034. Andhra Pradest

www.chalapathipharmacy.in Phone: 0863-2524124 Cell: +919440988884

stible of Phymacoutical Sciences (Attonomous)
Chatapathi Nagar, LAM, GURFUR, 34

only les Mr. SANDIP SHAH

President & CEO Market Access Solutions LLC (MKTXS), 575 Route 28, Building 2 Suite 2200, Raritan NJ 08868, USA.

http://www.mktxs.com Phone: +1908-864-4090 Cell: +1908-391-3398

Chalapathi Institute of Pharmaceutical Sciences

(Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.



ఆంధ్రప్రవేశ్ आंध्र प्रदेश ANDHRA PRADESH

SL No: 10267 Date: 29/10/2021 Rs: 2017
Sold to Y. V. Amja neguly S/o feet a ramaial, Crutw
For Whom Cheller H. The titute of Pharmacutical Sciences.

66AA 887673

NDA MOHAN REDDY
LICENCED STAMP VENDOR
L.No: 07-14-010/2014
R.L. No: 07-14-005/2021
D.No: 19-71, TADIKONDA

(MoU)

BETWEEN



CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES (AUTONOMOUS) CHALAPATHI NAGAR, LAM, GUNTUR

AND



PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

ARETE IT Services Pvt. Ltd., Vijayawada

MEMORANDUM OF UNDERSTANDING

This Memorandum of Understanding (hereinafter called as the "MoU" is entered into on this the 2nd day of February-Two thousand Nineteen (2019).

BETWEEN

Chalapathi Institute of Pharmaceutical Sciences (Autonomous), Chalapathi Nagar, Lam, Guntur-522034, the First party represented herein by its Prof.Rama Rao Nadendla, Principal, (hereinafter referred as "First party", the institution which expression, unless excluded by or repugnant to the subject or context shall include its successors – in- office, administrators and assigns).

AND

ARETE IT Services Pvt. Ltd., 40-5-10/A, Spice-Inn Building, Beside DV Manor Hotel, Tikkle Road, Vijayawada, the Second party, and represented herein by its MANAGING DIRECTOR, N.Vara Prasad (hereinafter referred to as "Second party", company which expression, unless excluded by or repugnant to the subject or context shall include its successors – in- office, administrators and assigns).

(First Party and Second Party are hereinafter jointly referred to as "Parties" and individually as "Party")

WHEREAS:

- A) First Party is Chalapathi Institute of Pharmaceutical Sciences (Autonomous), Chalapathi Nagar, Lam, Guntur-522034,
- B) First party and second party believe that collaboration and co-operation between themselves will promote more effective use of each of their resources and provide each of them with enhanced opportunities.
- C) The parties intent to cooperate and focus their efforts on cooperation within area of Skill Based Training, Education and Research.
- D) Both parties, being legal entities in themselves desire to sign this MoU for advancing their mutual interest;
- E) -ARETE IT Services Pvt. Ltd., the second party is engaged in business, software consultancy, skill development, education and R & D services.

NOW THEREFORE, IN CONSIDERATION OF THE MUTUAL PROMISES SET FORTH IN THIS MOU, THE PARTIES HERE TO AGREE AS FOLLOWS:

CLAUSE 1 CO-OPERATION

- 1.1 Both parties are united by common interests and objectives and they shall establish channels of communication and co-operation that will promote and advance their respective operations within the **Institution** and its related wings. The parties shall keep each other informed of potential opportunities and shall share all information that may be relevant to secure additional opportunities for one another.
- 1.2 First party and second part co-operation will facilitate effective utilization of the intellectual capabilities of the faculty of first party providing significant inputs to them in developing suitable teaching / training systems, keeping in mind the needs of the industry, the second party.
- 1.3 The general terms of co-operation shall be governed by this MoU. The parties shall cooperate with each other and shall, as promptly as is reasonably practical, enter into all relevant agreements, deeds and documents (the "Definitive Documents") as may be required to give effect to the actions contemplated in terms of this MoU. The term of definitive documents shall be mutually decided between the parties. Along with the definitive documents, this MoU shall represent the entire understanding as to the subject matter hereof and shall supersede any prior understanding between the parties on the subject matter hereof.

CLAUSE 2 SCOPE OF THE MOU

- 2.1 The budding graduates from the institutions could play a key role in technological up-gradation, innovation and competitiveness of an industry. Both parties believe that close co-operation between the two would be of major benefit to the student community to enhance their skills and knowledge.
- 2.2 Curriculum Design: Second party will give valuable inputs to the first party in teaching / training methodology and suitably customize the curriculum so that the students fit into the industrial scenario meaningfully.
- 2.3 Industrial Training and Visits: Industry and institution interaction will give as insight into the latest developments / requirements of the industries; the second party to permit the faculty and students of the first party to visit its group companies and also involve in industrial training programms for the first party. The industrial training and exposure provided to students and faculty through this association will build confidence and prepare the

- students to have a smooth transition from academic to working career. The second party will provide its labs / workshops / industrial sites for the hands-on training of the learners enrolled with the first party.
- 2.4 Internships and placement of students: Second party will actively engage to help the delivery of the internship and placement of students of the first party into internships/jobs, as per AICTE internship policy. The second party will also register itself on AICTE internship policy portal for disseminating the internship opportunities available with them.
- 2.5 Research and Development: Both parties have agreed to carry out the joint research activities.
- 2.6 **Skill Development Programms:** Second party to train the students of first party on the emerging technologies in order to bridge the skill gap and make them industry ready.
- 2.7 Guest Lecture: Second party to extend the necessary support to deliver guest lectures to the students of the first party on the technology trends and in house requirements.
- 2.8 Faculty Development Programs: Second party to train the faculties of first party for imparting industrial exposure / training as per the industrial requirements considering the national occupational standards in concerned sector, if available.
- 2.9 Both parties to obtain all internal approvals, consents, permissions and licenses of what so ever nature required for offering the programs on the terms specified herein.
- 2.10 There is no financial commitment on the part of the CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES (AUTONOMOUS), CHALAPATHI NAGAR, LAM, GUNTUR, the first party to take up any program mentioned in the MoU. If there is any financial consideration, it will be dealt separately.

CLAUSE 3 INTELLECTUAL PROPERTY

3.1 Nothing contained in this MoU shall, by express grant, implication, estoppels or otherwise, create in either party any right, title, interest, or license in or to the intellectual property (including but not limited to know-how, inventions, patents, copy rights and designs) of the other party.

CLAUSE 4 VALIDITY

- 4.1 This agreement will be valid until it is expressly terminated by either party on mutually agreed terms, during which period CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, CHALAPATHI NAGAR, LAM, GUNTUR, the second party, as the case may be, will take effective steps for implementation of this MoU. Any act on the part of training partner or ARETE IT Services Pvt. Ltd., the second party after termination of this agreement by way of communication, correspondence etc., shall not be construed as an extension of this MoU.
- 4.2 Both parties may terminate this MoU upon 30 calendar days notice in writing. In the event of termination, both parties have to discharge their obligations.

CLAUSE 5 RELATIONSHIP BETWEEN THE PARTIES

5.1 It is expressly agreed that **first party** and **second party** are acting under this MoU as independent contractors, and the relationship established under this MoU shall not be construed as a partnership. Neither party is authorized to use the other party's name in any way, to make any representations or create any obligation or liability, expressed or implied, on behalf of the other party, without the prior written consent of the other party. Neither party shall have, nor represent itself as having, any authority under the terms of this MoU to make agreements of any kind in the name of or binding upon the other party, to pledge the other party's credit, or to extend credit on behalf of the other party.

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences

(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34

Any divergence or difference derived from the interpretation or application of the MoU shall be resolved by arbitration between the parties as per the Arbitration Act, 1996. The place of the arbitration shall be at district head quarters of the first party. This undertaking is to be construed in accordance with Indian Law with exclusive jurisdiction in the courts of Guntur.

AGREED:

For Name of Institution Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

For Name of Industry ARETE IT Services Pvt. Ltd.,

Chalapathi Institute of Pharmaceutical Sciences (Autonomous) Chalapathi Nagar, LAM, GUNTUR-34

Chalapathi Institute of Pharmaceutical Sciences (Autonomous)	ARETE IT Services Pvt. Ltd.,
Chalapathi Nagar, Lam, Guntur- 522034, Andhra Pradesh	40-5-10/A, Spice-Inn Building, Beside DV Manor Hotel, Tikkle Road, Vijayawada, Andhra Pradesh-520010
Prof.Rama Rao Nadendia	Sri N.Vara Prasad, MD
Email: nadendla2000@yahoo.co.in	varaprasad@areteservices.org
www.chalapathipharmacy.in	www.areteservices.org
Mobile: 9440101685	Mobile:

Witness 1: P. Khampalultalia (PBHANU PRAKASH)

Witness 2: M. V. Ramaman (2) (MVENKATA RAMANA)

Witness 3: Pallavi Vadlamudi)

Witness 4: N. Santhi Priga 02/03/19 (Nagam. Santhi Priga)

PRINCIPAL



မဝင်္ပုပ်င်္က आंध्र प्रदेश ANDHRA PRADESH

SI No: 10859 Date: 27/102021 As: 201 sold 10 Y.V. Anjaneyalu s/o sectora maiah. Crutur. or whom Chalapathi Instituk of Pharmacutical Sciences.

66AA 887665

KONDA MOHAN REDDY LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

MEMORANDUM OF UNDERSANDING BETWEEN
CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR
AND

M/S. Arsvil Research Laboratories
COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

Aravil Research Laboratories, having its Office at 11 - 33 - 3/2, Thatakulavari street, post box no 183, Vijayawada, Andhra Pradesh. (hereinafter referred to as "ARSVIL RESEARCH LABORATORIES"):

And

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Gustur-522 034, Andhra Pradesh, India (hereinafter referred to as "Chalapathi Institute of Pharmaceutical Sciences");

WHICERAS:

Chalapathi Institute of Pharmaceutical Sciences and ARSVIL RESEARCH LABORATORIES believe that in order to explore the potential business relationship between Chalapathi Institute of Pharmaceutical Sciences and ARSVIL RESEARCH LABORATORIES with regard to formulation and analytical method development of the Active Pharmaceutical Ingredient, any of the parties herein may disclose certain Confidential Information to the For the purpose of this Agreement, the party(ies) disclosing Confidential Information will be referred to as the "Disclosing Party(ies)" and the parties that will receive the Confidential Information will be referred to as the "Receiving Party" Therefore, in consideration of the disclosure of the Confidential Information, ARSVIL RESEARCH Chalapathi Institute of Pharmaceutical Sciences agree as under Chalapathi Institute of Pharmaceutical Sciences LABORATORIES

- 1. Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - All information and know-how whether in written, electronic or (a) visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques, drawings, equipment, methods, designs, projected financials, any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates; and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and
 - (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.

- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, Without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other that for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- Upon written request of this disclosing party, the receiving party shall 5. return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files solely for archival purposes.

- 6. Title to, and all rights emanating form the ownership of, all Confidential Information disclosed Under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the parties.
- 7. Confidential Information shall remain subject to this Agreement for a period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- 8. Thee execution and performance of this agreement does not obligate the parties to enter into any other agreement or to perform any obligations other than specified herein.
- 9. The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- 10. No failure or delay by the disclosing party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

- The parties hereby agree that this Agreement represents the entire 11. agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government with out reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- 12. This agreement shall be binding on each party's successors and assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

Arsvil Research Laboratories

Chalapathi Inst. of Pharm. Sciences

By

/

Nama

N. S.

Title: Proprietor

By : 10016 24.05.2014

PRINCIPAL

Chalapathi Institute of Pharmacentical Sciences Citalapathi Nagar, LAM, GUNTUR-34

Name: Prof.Rama Rao Nadendla

Title: Principal cum Professor

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences

Chalapathi Nagar, LAM, GUNTUR-34.



SI NO: 10278 Date: 29/0/2021 Rs: 201

Soil 10 Y.V. As janeyour s/o lectaramaich. Control
For Whom Chalapath Institute of Pharmacutical Sciences
MEMORANDUM OF UNDERSAGOING DETWEEN

KONDA MOHAN REDDY LICENCED STAMP VENDOR L.No: 07-14-010/2014

R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

Chalapathi institute of Pharmageutical Sciences, Guntur

M/S. SRINIJA PARENTERALS
COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

SRINIJA PARENTERALS, having its Office at Door No. 283, Doctors Estate, Parecherla, Guntur (Dt.), Andhra Pradesh, India. (hereinafter referred to as "SRINIJA PARENTERALS");

And

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522 034, Andhra Pradesh, India (hereinaster referred to as "Chalapathi Institute of Pharmaceutical Sciences");

WHEREAR :

Chalapathi Institute of Pharmaceutical Sciences and Srinija Parenterals believe that in order to explore the potential business relationship between Chalapathi Institute of Pharmaceutical SRINIJA Sciences and PARENTERALS with regard to formulation and analytical method development of the Active Pharmaceutical Ingredient, any of the parties herein may disclose certain Confidential Information to the other parties. For the purpose of this Agreement, the party(ies) disclosing Confidential Information will be referred to as the "Disclosing Party(ies)" and the parties that svill receive the Confidential Information will be referred to as the "Receiving Party" Therefore, in consideration of the disclosure of the Confidential Information, SRINIJA PARENTERALS and Chalapathi Institute of Pharmaceutical Sciences agree as under:

Chalapathi Institute of Pharmaceutical Scient

Chalapathi Nagar, LAM, GUNTUR-3

- 1. Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - All information and know-how whether in written, electronic or (a) visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques, drawings, equipment, methods, designs, projected financials, any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates: and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and
 - (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.

- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, Without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other that for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- Upon written request of this disclosing party, the receiving party shall 5. return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files solely for archival purposes.

- 6. Title to, and all rights emanating form the ownership of, all Confidential Information disclosed Under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the parties.
- 7. Confidential Information shall remain subject to this Agreement for a period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- 8. Thee execution and performance of this agreement does not obligate the parties to enter into any other agreement or to perform any obligations other than specified herein.
- 9. The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- 10. No failure or delay by the disclosing party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

- The parties hereby agree that this Agreement represents the entire 11. agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government with out reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- This agreement shall be binding on each party's successors and 12. assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

Srinija Parenterals

Chalapathi Inst. of Pharm. Sciences

For SRINIJA PARENTERALS

AUTHORISED SIGNATORY

Name: Mr.Kamana Venkata Ranga Rao

Name: Prof. Rama Rao Nadendla

Title: Proprietor Title: Principal cum Professor

> Chalapathi Institute of Pharmaceutical Sciences Chalapathi Nagar, LAM, GUNTUR-34.



SL No: 10277 Date: 29/10/20 21 As: 201
Sold to Y.V. Anjaneyulu 8/0 feet a romaich, Gut V
For Whom Chalanothi Institute of Pharmacutical Sciences

KONDA MOHAN REDDY

LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA

GUNTUR Dt. Cell: 9866368173

memorandum of undersanding between Chalapathi institute of pharmaceutical sciences, guntur and

m/s. Organic Pharmaceuticals. Colloboration of Industry-Academic Interaction

ORGANIC PHARMACEUTICALS., having its Office at 54-18-37/4, All india Radio colony, Vijayawada-8, Andhra Pradesh, India. (hereinafter referred to as "ORGANIC PHARMACEUTICALS.");

And

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522 034, Andhra Pradesh, India (hereinafter referred to as "Chalapathi Institute of Pharmaceutical Sciences");

WHEREAS:

Chalapathi Institute Pharmaceutical ORGANIC *HARMACEUTICALS. that in order the potential business relationship between Chalapathi Institute ciences and ORGANIC PHARMACEUTICALS, with regard to formulation and analytical method development of the Active Pharmaceutical Ingredient, any of the parties herein may disclose certain Confidential Information to the For the purpose of this Agreement, the party (ies) disclosing confidential Information will be referred to as the "Disclosing Party (ies)" and the parties that will receive the Confidential Information will be referred to as the "Receiving Party" Therefore, in consideration of the disclosur Information, **ORGANIC** PHARMACEUTICAL Ghalapathi Institute of Pharmaceutical Sciences agree as underath institute of Pharmaceutical Sciences

(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

ŝ

- 1. Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - All information and know-how whether in written, electronic or (a) visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques, drawings, equipment, methods, designs, projected financials, any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates; and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and
 - (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.

- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other than for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- 5. Upon written request of this disclosing party, the receiving party shall return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses. compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files solely for archival purposes.

- 6. Title to, and all rights emanating from the ownership of, all Confidential Information disclosed under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the parties.
- 7. Confidential Information shall remain subject to this Agreement for a period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- 8. Thee execution and performance of this agreement does not obligate the parties to enter into any other agreement or to perform any obligations other than specified herein.
- 9. The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- 10. No failure or delay by the disclosing party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

- 11. The parties hereby agree that this Agreement represents the entire agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government without reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- 12. This agreement shall be binding on each party's successors and assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

50

ORGANIC PHARMACEUTICALS

FOR OLICIANIC PLANTING COUTLICALS

Rv

Monaging Partner

CHALAPATHI INST. OF PHARM. SCIENCES

D.,

PRINCIPAL

Chalapathi institute of Pharmaceutical Sciences
Chalapathi Nagar, LAM, GUNTUR-34

Name: Dr. D. Lakshmana Reddy Name: Prof.Rama Rao Nadendla

Title: Managing Director Title: Principal cum Professor



ಅಂ(ಡೈಪವ್ರೆಕ್ಟ್ आंध्र प्रदेश ANDHRA PRADESH SL No: 10273 Date: 28/10) 20 11 Rs: 20/

so scetaramaich austur y.v. Briancyely titute of Pharma Cutical Sciences R.L. No: 07-14-010/2014 D. No: 19-71, TADIKONDA

KONDA MOHAN REDDY LICENCED STAMP VENDOR L.No: 07-14-010/2014

GUNTUR Dt. Cell: 9866368173

MEMORANDUM OF UNDERSANDING BE AND

boratories Limited COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

Laboratories Limited, having its Office at 40-9-60, Kohinoor Benz Circle, Vijayawada. Andhra Pradesh. nafter referred to as "P V S Laboratories Limited");

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522 034, Andhra Pradesh, India (hereinafter referred "Chagapathi Institute of Pharmaceutical Sciences");

WHEREAS:

For Whom Chalapathi

Chalapathi Institute of Pharmaceutical Sciences and P V S Laboratories Limited believe that in order to explore the potential business relationship between Chalapathi Institute of Pharmaceutical Sciences Laboratories Limited with regard to formulation and analytical method development of the Active Pharmaceutical Ingredient, any of the parties herein may disclose certain Confidential Information to the other parties. For Agreement, the disclosing Confidential Information will be referred to as the "Disclosing Party(ies)" and the parties that will receive the Confidential Information will be referred to as the Therefore, in consideration of the disclosure Confidential Information, P V S Laboratories Limited and Chal PRINCIPAL Instigute of Pharmaceutical Sciences agree as under:

- Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - All information and know-how whether in written, electronic or (a) visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques, drawings, equipment, methods, designs, projected financials, any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates; and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and

- (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.
- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, Without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other that for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- Upon written request of this disclosing party, the receiving party shall 5. return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files solely for archival purposes.

- Title to, and all rights emanating form the ownership of, all Confidential 6. Information disclosed Under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the
- Confidential Information shall remain subject to this Agreement for a 7. period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- Thee execution and performance of this agreement does not obligate the 8. parties to enter into any other agreement or to perform any obligations other than specified herein.
- The receiving party agrees that the disclosure of Confidential 9. Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- No failure or delay by the disclosing party in exercising any right, 10. power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.

- The parties hereby agree that this Agreement represents the entire 11. agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government with out reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- 12. This agreement shall be binding on each party's successors and assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

P V S Laboratories Limited

Chalapathi Inst. of Pharm. Sciences

By : Declin

By

Chalapathi Institute of Pharmaceutical Sciences Chalapathi Nagar, LAM, GUNTUR-34

Name: Dr. Seshaiah V. Pamulapati

Name: Prof.Rama Rao Nadendla

Title: Chairman & Managing Director

Title: Principal cum Professor



ಆಂಥ್ರಿಪವೆ है आंध्र प्रदेश ANDHRA PRADESH SL No: [0272 Gate: 29/10/2021 Rs 201 Satasamaiah, autur Y.V Arijaneyuly 8/10 For Whom Edulapathi Institute of Pharmacutical Sciences R.L. No: 07-14-010/2014

Lam: GUNTER DE CET 9866368173

KONDA MOHAN REDDY

LICENCED STAMP VENDOR L.No: 07-14-010/2014

MEMORANDUM OF UNDERSANDING BETWEEN APATH! INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR AND

M/S. INTERNATIONAL HEALTH CARE LIMITED COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

International Health Care Limited, having its Office at 40-9-60, Kohinoor Apartments, Kalanagar, Benz Circle, Vijayawada, Andhra Pradesh. (hereinafter referred to as "INTERNATIONAL HEALTH CARE LIMITED");

And

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522 034, Andhra Pradesh, India (hereinafter referred to as "Chalapathi Institute of Pharmaceutical Sciences");

WHEREAS:

Chalapathi Institute of Pharmaceutical Sciences and INTERNATIONAL HEALTH CARE LIMITED believe that in order to explore the potential business relationship between Chalapathi Institute of Pharmaceutical Sciences and INTERNATIONAL HEALTH CARE LIMITED with regard to formulation and analytical method development of the Active Pharmaceutical Ingredient, any of the parties herein may disclose certain Confidential Information to the other parties. For the purpose of this Agreement, the party(ies) disclosing Confidential Information will be referred to as the "Disclosing Party(ies)" and the parties that will receive the Confidential Information will be referred to as the "Receiving Party" Therefore, in international Health Care Limited and Chamber Institute of Institute of PRINCIPAL Pharmaceutical Sciences agree as under:

> (Autonomous) Chalapathi Nagar, LAM, GUNTUR-24

- 1. Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - All information and know-how whether in written, electronic or (a) visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques, drawings, equipment, methods, designs, projected financials, any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates; and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and

His www.s.ws.ws.wo

- (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.
- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, Without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other that for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- Upon written request of this disclosing party, the receiving party shall 5. return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files solely for archival purposes.

- 6. Title to, and all rights emanating form the ownership of, all Confidential Information disclosed Under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the parties.
- 7. Confidential Information shall remain subject to this Agreement for a period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- 8. Thee execution and performance of this agreement does not obligate the parties to enter into any other agreement or to perform any obligations other than specified herein.
- 9. The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- 10. No failure or delay by the disclosing party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

- 11. The parties hereby agree that this Agreement represents the entire agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government with out reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- 12. This agreement shall be binding on each party's successors and assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

International Health Care Limited Chalapathi Inst. of Pharm. Sciences

By

FOR INFERMATION

Name: Dr.Seshaiah V.Pamulapati

Managing Director

By

24.05.2014

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences

Chalapathi Institute of Pharmaceutical Sciences

Chalapathi Institute of Pharmaceutical Sciences

Name: Prof.Rama Rao Nadendla

Title: Chairman & Managing Director

Title: Principal cum Professor

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)



అంద్రప్రదేశ్ आंध्र प्रदेश ANDHRA PRADESH

KONDA MOHAN REDD

SL NO: 10265 Date: 29/10 2021 Rs: 901

LICENCED STAMP VENDOR L.No: 07-14-010/2014

Anjanegaly élo secta samaidh, Crudur To chi Luce Albuma Cutical Sciences . R.L. No: 07-14-005/2021
D.No: 19-71, TADIKONDA
GUNTUR Dt. Cell: 9866368173

This Memorandum of Understanding (her to as "MOU") has day of Tuly, in agreed, made and executed on this 2021 ("Execution Date")

Part Traceron In

HEARTFULNESS EDUCATION TRUST, a registered trust having registered office at no. 40-15-9/12, Nandamuri Road, Venkateswarapuram it Office, Vijayawada - 520010, Andhra Pradesh, India(hereinafter referred to as "HET", which expression shall unless repugnant to the context and meaning thereof mean and include its successors, administrators, horized representatives and permitted assigns);

And

CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES(CLPT) is established by Chalapathi Educational society, which has been imparting high quality Pharmacy Education and Research since 2004. The Institute has high quality Pharmacy Education and Research since 2004. The institute has been offering four years bachelor's degree in Pharmacy (B.Pharmacy), two years Postgraduate Degree in Pharmacy (M.Pharmacy) in 05 specialisations, six years of Doctor of Pharmacy (Pharm.D), three years Post Baccalaureate course (Pharm.D-Post Baccalaureate) and Doctor of Philosophy (PhD) in Piparmacy. CLPT is permanently affiliated to Acharya Nagarjuna University recognized by UGC under section 2(f) and 12B and Department of Science and Industrial Research for research activities. The Institute is accredited by NAAC with "A" grade (excellent) and secured 3.16 CGPA on 4 scale and also certified by UGC from 2016-2017.

The campus is located in Chalapathi Nagar, Lam, Guntur, Andhra Pradesh,

(HET and CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES shall herein after be collectively referred to as the "Parties" and individually rred to as "Party" in this MOU)

Chalapathi Institute of Pharmaceutical Sciences HET is a public charitable trust registered under the Indian TrustoActive 882

inter alia with an objective to impart Heartfulness approach to various wellness programmes including relaxation, meditation, values based educational programmes for schools, colleges, government organizations, corporate etc., made available to all who are willingly interested in individual development and wellbeing. HET is also engaged in conducting various Teachers' training programmes in collaboration with Certain State Governments/ Education Institutions.

- ii) **HET** through its Heartfulness initiatives offer a way for balanced living through various meditation techniques. These simple and effective techniques gradually imbibe feelings of discipline, empathy, brotherhood, leading to mental, spiritual, and psychological well-being, helping an individual to transform not only inwardly but also his/ her attitudes, and dealings with society at large.
- chalapathi institute of Pharmaceutical sciences, and practices provided by HET on the terms agreed to herein, in order to stimulate and facilitate the development of programmes/modules which serve to enhance educational, social, spiritual & emotional development of students. Further, HET and CLPT in support of their interest in the field of education are desirous of promoting mutual cooperation by organizing and conducting educational workshops for mental, spiritual and psychological well-being of its students, and desire to extend the basis for friendly and cooperative collaboration by way of this MOU.

NOW THEREFORE, THE PARTIES HEREBY AGREE AS UNDER:

1. PURPOSE AND OBJECTIVES

1.1. Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh desires to create a precedent by offering suitable and pertinent learning and offerings to its students so as to enable them to lead their lives with purpose and be of help to the society at large. Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh has represented that it is a leading university that offers high quality education and its priority is to provide its students values, inner development enabling them to perform better in their education& be leaders in nation building. It seeks to provide

its students basic life skills to manage challenges in their relationships, avoid intoxicating abuses, digital dependence and deal with stress of

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

1000

modern life. It aims to enable their students and staff to de-stress, manage life's challenges in healthy ways and find joy, purpose and fulfilment. This will directly enhance their academic and work performance and create a harmonious environment within Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh.

- 1.2. HET has agreed to be helpful in such mission through its offerings as listed out in Schedule 1 ("Offerings"). [HET may also conduct a thorough teacher and administrative staff training program in Heartfulness approach for their inner development so as to enable them to encourage students in this program].
- 1.3. Both the Parties, hereby express their commitment to collaborate with each other to conduct (i) educational, (ii) Heartfulness relaxation, meditation and (iii) other connected wellness workshops to help students teachers to regulate their minds, moderate their tendencies, increase their concentration, sharpen the use of their will, introspect and self-analyse and accept people and situations in general. Through such workshops and Offerings of HET, they intend to help the students to improve their learning skills and behaviour, and inculcate humility, emotional maturity, confidence, stress management, self-awareness and most importantly, develop a sense of purpose towards life.

2. FACILITATORS

Both Parties shall nominate one or more representatives, who shall be the point of contact/ facilitator ("Facilitators") for the purposes of this MOU. The Facilitators of the respective Parties shall maintain regular contact with each other. Further, they shall propose and review the response received from the participants for the workshops and other activities that may be conducted pursuant to this MOU and in furtherance to fulfilling the purpose and objectives envisioned under this MOU.

3. RESOURCES

3.1. Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh shall make arrangements at its agreed venue(s) with required reference and reading material as specified by HET, by a establishing a (i) heartfulness corner in their library, and (ii) meditation practice room, and

by providing such audio-visual equipment and other facilities as shall be

required for conduct of the workshops and/or programmes with respect to the Offerings.

- 3.2. **HET** shall nominate such teachers, trainers and support staff as it deems necessary for conducting and providing training to participants at these workshops and programs pursuant to this MOU.
- 3.3. HET shall provide support to orient National Institute of Technology Andhra Pradesh's teachers to conduct the sessions as advised by HET for the students at Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh and shall provide such external support as required. Through these Offerings HET will make students at Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh understand values and their role in improving the quality of their life and enable them to impart spiritual training as an extended activity in its institutions as and when feasible.
- 3.4. The Parties agree to distribute reading materials/ promotional/ literature to the participants, through any means including but not limited to audio and/or video recordings, books and magazines as deemed fit by HET. HET shall share the content of such reading materials, literature, video recordings and other such material with Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh, before distributing the same to the participants.
- 3.5. The Parties further agree that at **HET's** discretion, they shall set up stalls at the program venue to distribute promotional items including but not limited to clothing, apparel, mementoes, brochures, other merchandise and/or articles and details of the programme etc.
- 3.6. The Offerings detailed in Schedule 1 shall be the scope of service to be rendered by HET which will be adhered to by HET during the term of this MOU.
 - 4. OTHER OBLIGATIONS OF CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, ANDHRA PRADESH
- 4.1. Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh shall extensively promote HET Offerings so that greater populace of students in National Institute of Technology Andhra Pradesh shall benefit from this initiative. As previously indicated in Clause 1.1 above, being a

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

0000

value-based model of education, **Chalapathi Institute of Pharmaceutical Sciences**, **Andhra Pradesh** may make all or any part of the Offerings, as applicable, a part of their curriculum for the students on a mutually agreed basis between the Parties.

4.2. Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh shall:

- i) Take initiatives such that its students shall attend the sessions conducted by HET with an objective to help them develop ideal value systems within to make them global citizens;
- ii) Facilitate students to integrate and imbibe such values into their lives and education;
- III) Jointly conduct surveys at regular interviews to find the effectiveness of the programs conducted pursuant to this MOU;
- iv)Encourage its students, faculty, staff and administration to share written, audio and/or video testimonials with respect to any training programs, workshops or seminars conducted by **HET**;

5. FINANCIAL UNDERSTANDING

- 5.1. HET shall provide its services with respect to Heartfulness meditation practices on free of charge basis at all times as agreed. However, it is hereby agreed that certain expenses relating to but not limited training programs, workshops and faculty shall be on a charged in the following manner. Chalapathi Institute of Pharmaceutical Sciences Andhra Pradesh shall bear the expenses:
 - i) Relating to the Offerings in terms of material, recommended readings, library heartfulness corner, meditation room(s) to be used by students and teachers at Chalapathi Institute of Pharmaceutical Sciences Andhra Pradesh shall be borne by Chalapathi Institute of Pharmaceutical Sciences Andhra Pradesh and the same would be set up as per the recommendations made by HET.

for training programs for faculty and students organised at HET centres, wherein an appropriate per diem expense would be undertaken

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh for boarding and lodging of the participants.

5.2. Logistic:

Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh shall reimburse all expenses with respect to (i) all actual to and from travel expenses, including but not limited to train, bus, flight and taxi, borne by all the HET trainers and special guests who are invited to Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh for conducting sessions/programs, (ii) food and (iii) other miscellaneous expense shall be reimbursed. Chalapathi Institute of Pharmaceutical Sciences Andhra Pradesh shall provide accommodation facilities to such trainers and special guests. HET shall provide such guidelines as necessary.

6. TERM

- 6.1. This MOU has been executed for the purpose of organizing workshops/ seminars/ training sessions at the premises of Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh or such other premises as may be mutually agreed upon in writing.
- 6.2. This MOU shall come into effect from the Execution Date and shall remain in force for a period of one year thereafter.
- 6.3. This MOU shall terminate after completion of the term of one year from the Execution Date, without any financial obligations of Parties, except for any pending reimbursements and costs as provided herein.
- 6.4. The Parties may execute similar agreements for similar initiatives in future or even extend the term of this MOU for such further periods as mutually agreed to by the Parties.
- 6.5. Either Party may voluntarily terminate this MOU by giving a 3 months' notice in writing to the other.
- 6.6. The provisions of this Clause 6.6 and 8 and all of its sub-clauses will survive any expiration or termination of this MOU.

7. ASSIGNMENT

This MOU is personal to the Parties and the rights and obligations established herein shall not be assignable by the Parties, except to the extent expressly permitted under this MOU or with the prior written consent of the other Party.

8. INTELLECTUAL PROPERTY

- 8.1. Neither Party shall exercise any rights in the trademarks, copyright or other intellectual property of the other Party, except as expressly stipulated herein.
- 8.2. All intellectual property rights including all (i) copyrights and other rights associated with works of authorship throughout the world, including neighboring rights, moral rights, and mask works, (ii) trade secrets and other confidential information, (iii) patents, patent disclosures and all rights in inventions (whether patentable or not), (iv) trademarks, trade names, internet domain names, and registrations and applications for the registration thereof together with all of the goodwill associated therewith, (v) all other intellectual and industrial property rights of every kind and nature throughout the world and however designated, whether arising by operation of law, contract, license, or otherwise, and (vi) all registrations, applications, renewals, extensions, continuations, divisions, or reissues thereof now or hereafter in effect ("IPR") with respect to(a) "Heartfulness", Relaxation", (c) "Heartfulness Meditation", (d) (b) "Heartfulness "Heartfulness Cleaning", their techniques and/or connected procedures therein and (d) the title and content/modules or any other information shared with Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh, it's staff, students and teachers, as the case may be, as part of the Offerings of HET, and (e) other trademarks belonging to HET or of those of its associates, (collectively referred to as "Heartfulness IP") as and when used by HET under license shall always vest with HET or its associates, as applicable. HET reserves the right to use the same internally or externally at its sole discretion.
- 8.3. This MOU in no way creates or conveys any ownership interests in Heartfulness IP to Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh. Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh shall only use such Heartfulness IP or any part thereof, in the manner and form previously approved in writing by HET and in coordination with and assistance of HET authorized representatives.

- 8.4. HET reserves the right to modify, change or improve such Heartfulness IP in the manner it deems fit and implement such changed versions of Heartfulness IP or wellness techniques at anytime during the term of this MOU.
 - 8.5. The Parties agrees that all ownership rights in any and all testimonials submitted in accordance with Clause 4.2 (iv) above shall vest with **HET**.

9. INDEMNITY

- 9.1. Except for cost reimbursements, the services provided by HET's with respect to the Offerings are on a mutual basis and free of cost. Only willing participants for their own wellbeing / self-development are required to participate. Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh may for development of its students make the HET programs, modules and/or workshops as part of its curriculum. The Parties, therefore, agree that such services do not give rise to any kind of damage or liability to anybody who participates and therefore no damage can arise there from. No indemnity is therefore provided herein. The Parties agree that that HET programs do not guarantee success of its objectives or purposes as mentioned anywhere in this MOU.
- 9.2. In the event Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh breaches the terms of Clause 8 (intellectual property) of this MOU, HET shall be entitled to seek specific performance against the Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh for performance of its obligations under Clause 8 (intellectual property) of this MOU in addition to any and all other legal or equitable remedies available to it.

10. GOVERNING LAW, JURISDICTION & ARBITRATION

10.1. This MOU shall be construed, interpreted and enforced in accordance with laws of India. In case of any differences between the Parties, they shall make all efforts to settle the disputes amicably through mutual discussion and negotiation within [• days], failing which, dispute(s) shall be referred to a sole arbitrator appointed by both the Parties, as per provisions of Arbitration and Conciliation Act, 1996. Language of arbitration shall be English and place of arbitration shall be [Vijayawada, Andhra Pradesh], 10.2.

Subject to the arbitration Clause 10.1 above, the courts of competent

jurisdiction at [Vijayawada] shall have exclusive jurisdiction with respect to any and all matters pertaining to this MOU.

11. MISCELLANEOUS

- f) This MOU together with any other documents including but not limited to memorandum of understandings, communications exchanged between the Parties defining responsibilities, obligations of both the Parties for different programs, initiatives etc. under this MOU, each of which shall be deemed to be an original, and all of which, taken together, shall constitute an integral part of this MOU constitute the entire agreement and supersedes any previous agreement between the Parties relating to the subject matter of this MOU.
- ii) This MOU can only be amended in writing by mutual consent of both the Parties. No modification or amendment to this MOU and no waiver of any of the terms or conditions hereof shall be valid or binding unless made in writing and duly executed by or on behalf of both the Parties.
- This MOU may be executed in counterparts and shall be effective when each Party has executed a counterpart. Each counterpart shall constitute an original of this Agreement.
- iv) If any provision of this MOU shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.
- v) The captions of the clauses of this MOU are for convenience of reference only and in no way define, limit or affect the scope or substance of any clause of this MOU.
- vi) The arrangement contemplated herein being in nature of cooperative strategic alliance for general wellbeing, no monetary consideration is involved except as provided for herein.
- vi) None of the provisions of this MOU as stated above shall be deemed to constitute a partnership between HET and Chalapathi Institute of Pharmaceutical Sciences, Andhra Pradesh and neither Party shall have any authority to bind or shall be deemed to be the agent of the other in any

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

Normalio

way. It is on principle to principle basis.

IN WITNESS WHERE OF the Parties here to have executed this MOU, in duplicate, by their duly authorized representatives on the date, month and year first written above.

For

HEARTFULNESS **EDUCATION TRUST**

SRI S.RAMAKOTESHWAR RAO rkrsunkara@gmail.com **GUNTUR DISTRICT, A.P. ZONAL COORDINATOR**

Date: 12/07/21

For

Chalapathi Institute of **Pharmaceutical Sciences Andhra** Pradesh

Witnesses:

2) P. Behnuprakagh of Jacob (Azel professor)



ಆಂಥ್ರಿಪಿದ್ದೆ शिष्ट्र अग्नि प्रदेश ANDHRA PRADESH SL No: 10 3400 20: 1 11 2021 Rs: 20/ 80 Seedurumaiah. Gutw sold to Y.V. Anjaneyulu Pharmacutical Scien For whom Chalapathi Instit MEMORANDUM OF UNDERSANDING PHARMACEUTICAL SCIENCES, GUNTUR

KONDA MOHAN REDDY LICENCED STAMP VENDOR L.N 5: 07-14-010/2014

R.L. No: 07-14-005/2021 D.No. 19-71, TAD KONDA

AND

M/S. DARWIN FORMULATIONS PVT.LTD. COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

DARWIN FORMULATIONS PVT. LTD., having its Office at 54-18-37/4, All India Radio colony, Vijayawada-8, Andhra Pradesh, India. (hereinufter refeared to as "DARWIN FORMULATIONS PVT. LTD.");

And

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Gurgur-522 034, Andhra Pradesh, India (hereinafter referred to as "Chalapathi Institute of Pharmaceutical Sciences");

WHEREAS:

Chalapathi Institute of Pharmaceutical Sciences and DARWIN FORMULATIONS PVT. LTD. believe that in order to explore the potential business relationship between Chalapathi Institute of Pharmaceutical Sciences and DARWIN FORMULATIONS PVT. LTD. with regard to formulation and analytical method development of the Active Pharmaceutical ingredient, any of the parties herein may disclose certain Confidential Information to the other parties. For the purpose of this Agreement, the purty (ies) disclosing Confidential Information will be referred to as the "Disclosing Party (ies)" and the parties that will receive the Confidential Information will be eferred to as the "Receiving Party" Therefore, in consideration of the disclosure of the Confidential Information, DARWIN FORMULATIONS PVT LTD. and Chalapathi Institute of Pharmaceutical Sciences agree RINCIPAL under:

- 1. Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - (a) All information and know-how whether in written, electronic or visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques. drawings, equipment, methods, designs, projected financials. any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates: and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and
 - (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.

- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other than for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- Upon written request of this disclosing party, the receiving party shall 5. return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files Moraolo solely for archival purposes.

- 6. Title to, and all rights emanating from the ownership of, all Confidential Information disclosed under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the parties.
- 7. Confidential Information shall remain subject to this Agreement for a period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- 8. Thee execution and performance of this agreement does not obligate the parties to enter into any other agreement or to perform any obligations other than specified herein.
- 9. The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- 10. No failure or delay by the disclosing party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

- 11. The parties hereby agree that this Agreement represents the entire agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government without reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- 12. This agreement shall be binding on each party's successors and assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

DARWIN FORMULATIONS PVT. LTD.

CHALAPATHI INST. OF PHARM. SCIENCES

By

By :

Name: Dr. D. Lakshmana Reddy

Name: Prof.Rama Rao Nadendla

Chalapathi Nagar, LAM, GUNTUR-34

Title: Managing Director

Title: Principal cum Professor

Chalapathi Institute of Pharmaceutical Sciences



అండ్స్పవదేశ్ आंध्र प्रदेश ANDHRA PRADESH SL No: 16270 Dite:29/16/2021 Rs 28

KONDA MOHAN REDDY D.No: 19-71, TADIKONDA GUNTUR DL. Cell: 98 68173

Assistance for Application for DST's Drugs and Pharmaceuticals Research Programme

sold to Y.V. Anjaneyulu

wralty, with its Comput at Chalapathi Nagar, LAM, Guntur \$22034, Andhra els, India (here in ofter, "Compus") and Inera Tech Consulting Services Private Limited, (here in "Consultant"), a company incorporated under Companies Act 2013, with office at Office No 456, 8 Orchard Road Mall, Royal Paims, Goregaon (East), Numbai-400066, Maharashtra, India.

o engage the services of "Consultant" for Application for DS1's Drugs a

"Assistance for Application for DST's Drugs and Pharmaceuticals Rese Project tick off date: Within Labors from the date of signifes contract End date: Within 12 days from the emilest list off date

Chalapathi Institute of Pharmaceutical Scienaes (Autonomous) Chalapathi Nagar, LAM, GUNTUR-34_

LICENCED STAMP VENDOR

L.No: 07-14-010/2014 R.L. No: 07-14-005/2021



Ixora Tech Consulting Services Pvt Ltd

(CIN U72900HR2015PTCD56637)

Office No 450, B-Wing, Orchard Road Holf, Royal Palms, Goregaon (East), Mumbal-400065, Maharashtra, India Phone: +92-8976224183 E-mail: Info@ixora-group.com

- IMR 12,000/- payable to "Consultant" after it help "Client" to prepare proposal for DST's Drugs and Pharmaceuticals Research Programme. Mode of payment will be Bank Transfer.
- "Client" must be in receipt of "Consultant"'s invoice for services provided hereunder within 7
 days of the date that services are rendered or payment may not be made. Payments will be due
 to the "Consultant" within 3 days of receipt of the invoice by the "Client".

Invoices: The "Consultant" will invoice the "Client" as described above. Invoices shall be addressed to Prof.Rama Rao Nadendia, Principal of Chalapath Institute of Pharmaceutical Sciences, Chalapathi Nagar, LAM, Guntur 522034, Andhra Pradesk, India.

6. Personnel

Representatives: For the "Client", Prof.Rama Rao Nadendia, shall represent the "Client"'s interests under this Agreement, and is responsible for supervision of all aspects of this Agreement. For the "Consultant", Mr.Ranen Das, shall represent the "Consultant"'s interests and shall manage this project in accordance with this Agreement.

7. Record Retention

"Consultant" shall maintain the records relating to its performance of the Scape of Work in its files for a period of not less than Three (3) years following the expiration of this Agreement.

IXOIS Teeth Consulting Services Pyl. Ltd.



Ixora Tech Consulting Services Pvt Ltd

(CIN U72900HR201SPTC056637)

Office No 459, 8-Wing, Orchard Hood Mail, Royal Points, Geregeon (East), Mumbal-600065, Maharashtra, India Phone: +91-8976224183 E-mail: Info@biora-group.com

8. **General Provisions**

Governing Law: This Agreement, the rights and obligations hereunder, and any claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of Maharachtra, India without regard to the principles of conflicts of laws.

IN WITNESS WHEREOF, "Client" and "Consultant" have caused this Agreement to be executed by their duly authorized representatives as of the date first written above.

FOR CLIENT: Prof.Rama Rao Nadendia, FRINGO PAL Chalapathi Institute of Pharmaceuticai Sciences (Autonomous) Chalepathi Nagar, LAM, GUNTUR-84 Date Toch Consultation Service FOR CONSIDERANT: Mr.Ranen Das, Director PRINCIPAL Chalapathi Institute of Pharmaceutical Scienses

(Autonomous) Chalapathi Nagar, LAM, GUNTUR-34.



ఆం|ధ్యప్రదేశ్ ऑध्र प्रदेश ANDHRA PRADESH

SL No: 1034 Date: 1 11 20 21 As:201 sto sectavamaich, Gutur Sold to Y.V. Anjanequely

Pharmacufical Science

LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA

GUNTUR Dt. Cell: 9366368173

NUA MOHAN REDDY

MEMORANDUM OF UNDERSAMMING PHA (教育) (A (本) (本) (本) (本) AMD

M/S. DARWIN RESEARCH L COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

DARWIN RESEARCH LABORATORIES., having its Office at 54-18-37/4, All India Radio colony, Vijayawada-8, Andhra Pradesh, India. (hereinafter referred to as "DARWIN RESEARCH LABORATORIES.");

And

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522 034, Andhra Pradesh, India (hereinafter referred to as "Chalapathi Institute of Pharmaceutical Sciences");

WHEREAS:

Chalapathi Institute of Pharmaceutical Sciences and DARWIN RESEARCH LABORATORIES, believe that in order to explore the potential business relationship between Chalapathi Institute of Pharmaceutical Sciences and DARWIN RESEARCH LABORATORIES, with regard to formulation and analytical method development of the Active Pharmaceutical Ingredient, any of the parties herein may disclose certain Confidential Information to the other parties. For the purpose of this Agreement, the party (ies) disclosing Confidential Information will be referred to as the "Disclosing Party (ies)" and the parties that will receive the Confidential Information will be referred to as the Receiving Party" Therefore, in consideration of the disclosure of the Confidential Information, DARWIN RESEARCH LABORATORIES an Chalapathi Institute of Pharmaceutical Sciences agree as under: Chalapathi Institute of Pharmaceutical Sciences

(Autonomous) Chalapathi Nagar, LAM, GUNTUR-34.

- 1. Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - All information and know-how whether in written, electronic or (a) visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques, drawings, equipment, methods, designs, projected financials, any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates; and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and
 - (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.

- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

A COOPORCE

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other than for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- Upon written request of this disclosing party, the receiving party shall 5. return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files solely for archival purposes. (Onanole)

- 6. Title to, and all rights emanating from the ownership of, all Confidential Information disclosed under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the parties.
- 7. Confidential Information shall remain subject to this Agreement for a period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- 8. Thee execution and performance of this agreement does not obligate the parties to enter into any other agreement or to perform any obligations other than specified herein.
- 9. The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- 10. No failure or delay by the disclosing party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

- 11. The parties hereby agree that this Agreement represents the entire agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government without reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of both parties. If any provision of this Agreement is found to be unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- 12. This agreement shall be binding on each party's successors and assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

DARWIN RESEARCH LABOURATORIES

CHALAPATHI INST. OF PHARM. SCIENCES

By PROPRIETOR

By

Chalapathi Institute of Pharmaceutical Sciences
Chalapathi Nagar, LAM, GUNTUR-34

Name: Dr. D. Lakshmana Reddy

Name: Prof.Rama Rao Nadendla

Title: Managing Director

Title: Principal cum Professor

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)



ಆಂ|ಡ|ಏವೆ೯ आंध्र प्रदेश ANDHRAP SL No: 10275 Date: 29/10/209/ Rs: 20/

sectasa malah, autur

KONDA MOHAN REDDY LICENCED STAMP VENDOR L.No: 07-14-010/2014 Pharma Cutical Sciences R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

ii institute of pharmageutical sciences, guntur AND

M/S. DARWIN RESEARCH & AYUR PHARMA. OBORATION OF INDUSTRY-ACADEMIC INTERACTION

DARWIN RESEARCH & AYUR PHARMA., having its Office at 54-18-37/4, All India Radio colony, Vijayawada-8, Andhra Pradesh, India. (hereinafter referred to as "DARWIN RESEARCH & AYUR PHARMA.");

And

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Juntur-522 034, Andhra Pradesh, India (hereinafter referred to as Chalapathi Institute of Pharmaceutical Sciences");

WHEREAS:

For Whom

Chalapathi Institute of Pharmaceutical Sciences and DARWIN RESEARCH AYUR PHARMA, believe that in order to explore the potential business relationship between Chalapathi Institute of Pharmaceutical Sciences and MARWIN RESEARCH & AYUR PHARMA, with regard to formulation and analytical method development of the Active Pharmaceutical Ingredient, any of the parties herein may disclose certain Confidential Information to the other parties. For the purpose of this Agreement, the party (ies) disclosing Confidential Information will be referred to as the "Disclosing Party (ies)" and the parties that will receive the Confidential Information will be referred to as the "Receiving Party" Therefore, in consideration of the disclosure of the Confidential Information, DARWIN RESEARCH & AYUR PHARMA and Chalapathi Institute of Pharmaceutical Sciences agree as under Chalapathi Institute of Pharmaceutical Sciences

(Autonomous) Chalapathi Nagar, LAM, GUNTUR-34.

- 1. Definition of Confidential Information. "Confidential Information" is define to mean and include:
 - All information and know-how whether in written, electronic or (a) visual form, relating to or developed by the Disclosing Party and pertaining to the subject of this Agreement including but not limited to manufacturing or production information, technical details and specifications, know-how, data, formulae, techniques, drawings, equipment, methods, designs, projected financials, any computer programs and software, frameworks, process details, business models, marketing programs and plans, sales data, financial information, marketing information, business methods, business policies and procedures, pricing policies, intellectual property details, any information relating to existing or proposed business arrangements involving the Disclosing Party or its affiliates, operating policies or manuals, financial records and any other financial, commercial, business or technical information relating to Disclosing Party or any of its affiliates; and
 - (b) All disclosures that any employee or representative of Disclosing Party designates as confidential, either orally or in writing, prior to its disclosure; Provided that any oral information must be described in reasonable detail in writing, identified as Confidential Information and transmitted to the Receiving Party within thirty (30) days of the date of oral disclosure to the Receiving Party, and
 - (c) Any information gleaned by the Receiving Party during its visit to the premises or place of business of the Disclosing Party; and
 - (d) The terms and conditions of this Agreement and the existence of the discussions between Disclosing Party and Receiving Party to which this Agreement pertains.

- 2. The parties hereby agree that the following shall not be considered confidential information subject to this agreement:
 - (a) Information which, prior to the time of disclosure, is in the public domain;
 - (b) Information which, after disclosure becomes part of the public domain by publication or otherwise, provided that such publication is not in violation of this Agreement or, to receiving party's knowledge, any other confidentiality agreement;
 - (c) Information that the receiving party lawfully received from a third party, provided however, that such third party was not obliged to hold such information in confidence;
 - (d) Information that was independently developed by the receiving party, without reference to any Confidential Information as established by appropriate documentation; and
 - (e) Information that the receiving party is compelled to disclose by a court or other tribunal of competent jurisdiction, provided however, that in such case the receiving party shall immediately give as much advance notice as feasible to the providing party so that the providing party may seek a protective order or other remedy from said court or tribunal. In any event, the receiving party shall disclose only that portion of the Confidential Information that, in the opinion of its legal counsel, is legally required to be disclosed and will exercise reasonable efforts to ensure that any such information so disclosed will be accorded confidential treatment by said court of tribunal.

- 3. The receiving party shall not use nor disclose to any third party Confidential Information for any purpose other than for the purpose set forth in this Agreement. The parties hereby agree to hold in strictest confidence any and all Confidential Information disclosed by one party to the other under the terms of this agreement and shall use such information solely for the purpose of evaluating a potential business relationship and if a business relationships consummated, carrying out such business relationship.
- 4. The receiving party will not disclose any such Confidential Information to any person other than to its employees, agents, consultants and officers that have a need to know such information to effectuate the purpose of this Agreement and that such employees, agents, consultants and officers shall be informed of this Confidentiality Agreement and shall be bound by at least as restrictive terms as those contained in this agreement.
- Upon written request of this disclosing party, the receiving party shall 5. return promptly to the disclosing party (or, at the receiving party's option, destroy) all Confidential Information furnished to it, including any copies thereof and notes, extracts, or derivative materials based thereon (Provide that if the receiving party so opts to destroy, the receiving party shall confirm such destruction in writing to the disclosing party); and until this Agreement is terminated or until the expiration of the confidentiality obligations set forth in this Agreement, shall keep confidential and not use in any way detrimental to the disclosing party any analyses, compilations, studies, or other documents which reflect any of the Confidential Information. Not with standing thee foregoing provision, the legal counsel of both parties may retain one copy of the Confidential Information in its confidential files loa malo solely for archival purposes.

- 6. Title to, and all rights emanating from the ownership of, all Confidential Information disclosed under this Agreement shall remain vested in the disclosing party. Nothing herein shall be construed as granting any license or option, in favor of the receiving party, in such Confidential Information under any patent, copy right and / or any other rights now or hereafter by the disclosing party in or as a result of such Confidential Information other than as specifically agreed upon by the parties.
- 7. Confidential Information shall remain subject to this Agreement for a period of Ten (10) years beyond the date of disclosure or generation of such confidential Information.
- 8. Thee execution and performance of this agreement does not obligate the parties to enter into any other agreement or to perform any obligations other than specified herein.
- 9. The receiving party agrees that the disclosure of Confidential Information to any third party without the express written consent of the disclosing party will cause irreparable harm to the disclosing party, and that any breach or threatened breach of this agreement by the receiving party will entitle the disclosing party to seek injunctive relief, in addition to any other legal remedies available to it, in the court of competent jurisdiction.
- 10. No failure or delay by the disclosing party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power, or privilege hereunder.

- The parties hereby agree that this Agreement represents the entire 11. agreement between the parties with respect to the subject matter hereof and super cedes all prior and / or contemporaneous agreements and understandings between the parties with respect to the handling of Confidential Information, whether written, oral, visual, audio or in any other medium whatsoever. This Agreement shall be governed by the laws of Indian Government without reference to its conflict of laws rules. This Agreement may not be amended or in any manner modified except by a written instrument signed by authorized representatives of If any provision of this Agreement is found to be both parties. unenforceable, the remainder shall be enforced as fully as possible and the enforceable provision shall be deemed modified to the limited extent required to permit its enforcement in a manner most closely representing the intention of the parties as expressed herein.
- 12. This agreement shall be binding on each party's successors and assignees.

IN WITNESS WHEREOF, the parties hereto have executed this agreement of the day and year first above written.

DARWIN FORMULATIONS PVT. LTD.

CHALAPATHI INST. OF PHARM. SCIENCES

By

By

Name: Dr. D. Lakshmana Reddy

Name: Prof.Rama Rao Nadendla

Chalapathi Nagar, LAM, GUNTUR-34

Title: Managing Director

Title: Principal cum Professor

Chalapathi Institute of Pharmaceutical Sciences
(Automorphis)



ఆంధ్రప్రదేశ్, आंध्र प्रदेश ANDHRAPR

SL No 10 260 Date: 29/1620 21 Rs:20/

sold to Y. V Anjaneyuly

s/o lesta suraidh,

LICENCED STAMP VENDOR

L.No: 07-14-010/2014 R.L. No: 07-14-005/2021

THE DEPARTMENT OF

Govt. College for Women (A), Guatur

and

THE DEPARTMENT OF MICROBIOLOGY

Chalapati Institute of Phurmaceutical Sciences, Lam, Guntur

This seemorandum of Understanding (MOU) sets for the terms and understanding between the

The Department of Zoology, Govt. College for Women (A), Guntur

and

The Department of Pharmaceutics, Chalapati Institute of Pharmaceutical Sciences, Lam, Guntur

to share academic and laboratory resources

Background Government College for women, (Autonomous) is an Autonomous, NAAC A grade institution with CFE status. Chalapati Institute of Pharmaceutical Sciences, Lam, Guntur is an Autonomous NAAC A grade institution. Both have well equipped lab facilities and academic resources. Mutual understanding between these two colleges may strengthen the academic standards.

Purpose
This MOU will enrich our Teaching Learning process

The above goals will be accomplished by undertaking the following activities:

1. By sharing views regarding curriculum

2. By arranging invited lectures, workshops

Reporting
The In Charge of the Department

Funding

There is no financial commitment in this process

Three years i.e., from the academic year 2017-18 to 2019-20

Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

This MOU is at-will and may be modified by mutual consent of authorized officials from Govt. College for Women (A), Guntur and Chalapati Institute of Pharmaceutical Sciences, Lam, Guntur. This MOU shall become effective upon signature by the authorized officials from the Govt. College for Women (A), Guntur and Chalapati Institute of Pharmaceutical Sciences, Lam, Guntur and will remain in effect until modified or terminated by any one of the partners by mutual consent. In the absence of mutual agreement by the authorized officials from Govt. College for Women (A), Guntur and Chalapati Institute of Pharmaceutical Sciences, Lam, Guntur. This MOU shall end by the academic year 2019-20.

Contact Information:

Partner name :: Dr. Ch. Tulasi

Partner representative :: Department of Zoology

Position:: In charge of the Dept of Zoology Address :: Govt. College for Women(A),

Guntur

Tulen

Telephone:: 9000103952

E-mail:: anantha.tulasi@gmail.com

Partner name :: Dr. Rama Rao Nadendla

Partner representative :: Department of

Pharmaceutics

Position: Professor and Principal

Address:: Chalapati Institute of Pharmaceutical

Sciences, Lam, Guntur Telephone :: 9885968197

E-mail::

(Partner signature)

(Partner signature)

Date ::

Date :: 01 04 2017

Principal

Govt. College for Women

Guntur

- PRINCIPAL

GOVT. COLLEGE FOR WOMEN

GUNTUR

College Seal

Principal

Chalapati Institute of Pharmaceutical Sciences,

Lam, Guntur

Chalapathi Institute of Pharmaceutical Sciences

(Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34

College Seal

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences

(Autonomous)



ಆಂಥ ಏವೆ ह आंध्र प्रदेश ANDHRA PRADESH

SL No: 10264 Dec: 29/10/2021 Rs. 201 Sold 10 Y.V. Anjameyuly 8/0 Sectaromaich, Gutar For Whom Chalapathi Institute of Phomocutical Sc Institute of Phonomacutical Sciences.

Chalapathi Institute of Pharmaceutical Sciences Rubicon Skill Development Pvt. Ltd.

For Training students on Rubicon's Campus to Corporate Program

This Memorandum of Understanding is made at Pune on set day of July sing. Chalegathi Institute of Pharmaceutical Sciences, Andhra Pradesh. Hereinafter referred to as "THE COLLEGE" (Which term shall so far as the context admits be deemed to mean and include its successors and assigns) of the First Part,

AND

Rubicon Skill Development Private Limited a Company incorporated and registered under Companies Act, 2023, having its Corporate office at 803, 8th Floor, Tower 5, World Trade Centre, Pune -411014, Maharashtra, hereinafter referred to as "Rubicon" (which term shall so far as the context admits be deemed to mean and include its successors, administrators, executors and assignees) of the Second Part.

Introduction

THE COLLEGE has decided to partner with RUBICON for the conduct of Connect with Work Program (hereinafter referred to as "Training Program") at THE COLLEGE.

- THE COLLEGE Responsibilities:
 - Shall nominate one person with adequate accountability and responsibility to coordinate the Training Piogram. He / She would act as the single point of contact for the proposed
 - Shall make available the infrastructure (including IT infrastructure, applications and connectivity) required to conduct the Training Program.

PRINCIPAL Chalapathi Institute of Pharmaceutical Sciences (Autonomous) Chalapathi Nagar, LAM, GUNTUR-34.

LICENCED STAMP VENDOR

L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

elopnie

- 2.3. Shall provide all the support services and facilities to RUBICON during the conduct of the said Training Program. Adequate power backup through UPS and DG supplies during the training sessions
- 2.4. Shall coordinate with RUBICON and facilitate conduct of all the assessments including the assessment to be conducted by the external agency (if any) identified by RUBICON, as per schedule communicated by RUBICON.
- 2.5. Provide lodging, wherever available, as per the standards of RUBICON for faculty conducting the Training Programme for the total duration of the Training Programme plus two days (one day prior and one day after closure). The lodging so planned to be provided should be with independent room (with attached toilet), regular water supply, clean, with access to boarding facilities, should have well lit approach and surroundings, have adequate safety & protection and peaceful environment.
- 2.6. Shall share the details of students in a prescribed format to ensure that there is no duplication of beneficiaries
- 2.7. This is a multi-year program to create social impact. The college shall share few details to assess the impact of the program. For e.g. Placement details of trained students will be required to assess the impact of the program from one year to another year.

3. Rubicon Responsibilities:

- 3.2. Will provide necessary training as per Training Programme requirements and curriculum for delivery as per Annexural to this MOU
- 3.2. Will provide suitable faculties for the training exclusive for classroom training
- 3.3. Will conduct assessment of its own and also arrange external assessment as required.

PUNE SALIDON ON THE SERVICE OF THE S

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

4. Other Terms & Conditions:

The following are other terms and conditions of engagement:

- 4.1. Batch Size: The batch size would need to be a min/ max of 35-40.
- 4.2. Each student would be made available for the Training Program for specified number of hours per day for the duration of the Training Program
- 4-3. Pre-assessment & Selection: RUBICON may carry out pre-assessment of the students who have applied for the course and shortlist the select candidates to undergo the Training Program. The final decision on selection of candidates eligible to take the Training Program shall be with RUBICON.

4.4. Programme schedule:

- 4.4.1. Training Program scheduled commencement date 8th to 10th July -2019
- 4.4.2. Scheduled Completion Date: and will be completed by not later than : 1170 JUN 2019.

4.5. Commercials:

4.5.1. <u>Iraining Fees</u>: The training Fees is as follows,

Since this is a CSR funded Program there is no fee payable by THE COLLEGE for this Training Program

4-5-2. Payment Terms
Not Applicable

4.6. Certification:

Students who are successful in the assessment conducted by RUBICON shall be awarded a certificate post completion of the training program.

4-7- Term of engagement:

PUNE PUNE

PRINCIPAL
Chalapathi institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

This MoU is valid from the date of sign off by both parties for a period of Two years, however both parties agree that based on mutual agreement, the terms may be extended. Both parties also agree that terms may be renegotiated.

4.8. Limitations and Warranties:

Both parties agree that it would be their endeavour to prevent any liability arising out of default or non-compliance of the MoU terms by the other party.

4.9. Termination:

- 4.9.1. Both parties can terminate the MoU with a prior written thirty (30) day notice on default of terms of non-adherence to any condition or responsibilities by the other party as outlined in this MoU in case such default is not rectified within such 30 days.
- 4.9.2. Both parties also agree that it would be their professional endeavour that despite any termination of the MOU, progress would continue, without any prejudice to the ongoing Training Programmes, which would be without any hindrance and would be progressed for completion.

General Terms:

- Both the parties may receive information proprietary to other party (the Confidential Information) in the course of performance of their obligations under this MOU. Confidential Information is not meant to include any information which (a) is publicly available (b) is rightfully received by the parties from third parties without accompanying secrecy obligations; (c) is already in either party's possession and was lawfully received from sources other than the parties or (d) is independently developed by the parties. The two bodies understand and acknowledge that the Confidential Information is valuable and confidential and agrees that it will at all times be kept in trust to be disclosed only to such persons as have a "need to know" the same for the effective implementation of this MOU and that it will only be used by the parties for the benefit of others.
- 5.2. Both the parties understand and agree that all written or other tangible data and documentation developed or procured by the other party in performing its obligations under this MOU, whether in printed or electronic form, belongs to other party and that other party will have all rights, titles and interests therein.

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.

- 5.3. Both parties shall not use the name and brand of other party in any advertisement or make any public announcement without the prior written approval of the other.
- 5.4. Each party shall be at liberty to terminate this MOU with a written notice period of three (3) month to the other party without any compensation and seeking legal redress.

6. Jurisdiction:

in the event of any litigation, the court of jurisdiction shall be Pune.

7. indemnification

Both parties agree to indemnify each other and hold the other party harmless from and against any claim, loss, liability, or expense, including, but not limited to, damages, patent, and trademark infringement, costs and attorneys' fees, arising out of or in connection with any acts or omissions of their agents or employees, as related to the terms of this MoU.

Any claim, compensation, case initiated by any student against Asiemt in relation to the Training Program due to any acts or omissions of COLLEGE and/or RUBICON shall be defended and contested by the COLLEGE and RUBICON at their sole expenses and cost keeping Aricent indemnified from the same.

8. Limitation of Liability:

Except for the indemnification obligations, both parties agree that the liability would be limited to the amount of actual transactions between the two parties

a. Notices:

FUNE

Any notices under this MOU will be sent by certified or registered meil, return receipt requested, to the respective address of Parties as contained in this MOU. Such notice will be effective upon its mailing as specified.

10. Intellectual Property Rights

Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

- 10.2. RUBICON explicitly warrants that it owns all the intellectual properties related to content in all formats, the technology framework and all other related objects and the THE COLLEGE has no rights to use the content and mode of delivery for any other purpose.
- 10.2. Each party hereby undertakes to inform the other party of any violation of Intellectual Property Rights or its unlawful use, under prevalent laws of India Further, each of the party herein, agrees to co-operate with the other to the extent possible in the process of investigating such cases of any violation of Intellectual Property Rights or its unlawful use and taking legal action against the said infringement.
- 10.3. Upon expiration of this MoU, or two years period of time from the date of completion of the courses, whichever is later, each party hereby agrees that it shall not make any claim on the Trade Name or the copyrights of the other, which belongs exclusively to the other party, nor shall either party use any trade name which is deceptively or confusingly similar to the trade name of the other.

11. Force Maleure:

- 11.1. Neither party to this MOU shall be liable for any failure or delay on its part in performing any of its obligations under this MOU, if such failure or delay shall be result of or arising out of Force Majeure conditions and, provided that the party claiming Force Majeure shall use its best efforts to avoid or remove such cause of non-performance and shall fulfill and continue performance hereunder with the utmost dispatch whenever and to the extent such cause or causes are removed.
- Any extraordinary event, which cannot be controlled by the parties, shall for the purpose of this MOU be considered as a Force Majeure event. Such events include acts of God, acts or omissions of any Government or agency thereof, compliance with rules, regulations or order of any Government Authority. Provided however, if either party claims that existence of any of the aforesaid conditions is delaying or disabling the performance by said party of its obligations under this MOU, such party shall give immediate notice to the other party of the existence of such conditions whose existence are claimed to delay or disable the performance of obligations as aforesaid.

PRINCIPAL
Chalapathi institute of Pharmaceutical Sciences
(Autonomeya)
Chalapathi Nagar, LAM, GUNTUR-34.

IN WITNESS WHEREOF, to show their assent, the duly authorized representative of the parties hereto have signed the MoU and set their seals as below:-

Party of the First Part

For- Chalapathi Institute of Pharmaceutical Sciences

Stamp of the Party

Signature of Authorised Signatory:

Name of Authorised Signatory

Poot. RAHARAO NADENDLA

PRINCIPAL

Designation: PRINCIPAL Chalapathi institute of Pharmackines Pacience (Autonomous)
Chatepathi Nagar, LAM, GUNTUR-34.

Witness

Signature of Witness

9: N. V. Ramanaya 17:19.

Name of Witness

Party of the Second Part Stamp of the Party:

Signature of Authorised Signatory: Name of Authorised Signatory 1 - 1 - 94 5 43 8

Designation

For Rubicon Skill Development Pvt. Ltd.

Pravir Kumar

Chief Executive Officer

Witness

Signature

of

Witness

Name of the Witness

Chalapathi Institute of Pharmaceutical Sciences

(Autonomous) Chalapathi Nagar, LAM, GUNTUR-34,



ಆಂಧ್ರಕ್ಷದೆ हैं आंध्र प्रदेश ANDHRA PRADESH

Sold to Y. V. Abjaneyoly 8/0 sectator smalah, autur Sold to Y. V. Abjaneyoly 8/0 sectator smalah, autur For Whom Chalapathi Institute of Pharmacertical Sciences MEMORANDUM OF UNDERSORNE GENTREEN 66AA 887710 X

KONDA MOHAN REDDY LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173



HALAPATHI INSTITUTE OF PHARMACEUTICA SCIENCES, GUNTUR-522034

M/S. ANN PHARMACARE & WELLNESS LLP

TO CARRYOUT ACTIVITIES OF PHARMACARE TO GUNTUR PUBLIC AS PER FIP-WHO PHARMACEUTICAL CARE 2006

In accordance with the mutual desire to promote cooperation between Department of Pharmacy Practice, CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, Guntur-522034 and the "Centre for Community Services" of M/S. ANN PHARMACARE & WELLNESS LLP, Harpanahalli, Karnataka-576104, enter into this formal statement of collaboration in the form of Memorandum of Understanding (M.O.U.) for the purpose of Academic and Professional exchanges.

Both the institutions have found it mutually beneficial to explore cooperative activities for the following purposes.

- Training the Pharm.D Interns every year in the Ann Pharmacare and Wellness LLP for community Services.
- 2. The Interns should educate the patients registered in ANN
 Pharmacare and Wellness LLP regarding their illness and drugs for
 better patient care.
- 3. Conduct regular follow-up to the patients for the determined period.
- . To provide drug information services to the community.

It is understood that the details of joint activities/conditions for the utilization of results achieved, arrangements for specific visits, exchange and all other form of co-operation will be handled on mutually agreeable terms for each specific case.

Y.V.Anjaneyulu President Chalapathi Educational Lam, Gantur

Chalapathi Institute of Pharmaceutical Adaptive National National



ಆಂಧ್ರವದೆ है आन्ध्र प्रदेश ANDHRA PRADESH

Y. V. Anganyulu S/s Sulheramaian Priesident some Chale poster Indited appearance continued Sciences,

L'Erichenakermari BW 849333

> K. KRISHNA KUMARI LICENSED STAMP VENDOR L. No.07-15-015/2011 R.L. No.07-15-037/2017 BUDAMPADU, GUNTUR-17, Cell: 9704668675

MEMORANDUM OF AGREEMENT BETWEEN

ANDHRA PRADESH STATE SKILL DEVELOPMENT CORPORATION (First Party) AND

CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR (Second Party)

This Memorandum of Agreement (MoA) is entered into on 27th day of May, 2017.

The Andhra Pradesh State Skill Development Corporation, represented by the CEO, APSSDC having its registered office at NTR Administrative Block, 2nd Floor, above arrival block, Pandit Nehru RTC Bus Stand, Vijayawada - 520002 (here in after referred to as "APSSDC" or First Party, which expression shall unless repugnant to this context or meaning thereof, includes its successor in office, legal representatives and permitted assigns) of the One Part.

And

The Chalapathi Educational Society, registered under Provisions of Act XXI of 1860 bearing registration number 610 of 1995; represented by Sri Y.V.Anjaneyulu, President, having its registered office at Chalapathi Nagar, Lam, Guntur-522034; having a Educational Institution by the name Chalapathi Institute of Pharmaceutical Sciences, located at Chalapathi Nagar, Lam, Guntur (here in after referred to as "Employability Skill Centre, Chalapathi Educational Society", Second Party, which expression shall unless repugnant to this context or meaning thereof, includes its successor in office, legal representatives and permitted assigns) of the other Part.

1 | Page

Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

WHEREAS

- (a) The Government of Andhra Pradesh has a vision to be among the three best states in India by 2022 and to achieve the status of a developed state by 2029. To spearhead the skilling activities at the state level, a separate Department of Skill Development, Entrepreneurship and Innovation has been set up along with its implementing arm -Andhra Pradesh State Skill Development Corporation (APSSDC), the first party, as the forefront of all skilling initiatives in the State. Thus, the Corporation is in the business of promoting skill development and entrepreneurship among different segments in the State of Andhra Pradesh. In its endeavors to enhance the Employability Skills of Under Graduate and Post Graduate course perusing students, the first party intended to establish Employability Skills Centres (ESCs) and progressive UG/ PG colleges/ Autonomous institutions / Govt Colleges / University Campus PG colleges. In this direction, through this MOA, APSSDC intends to associate with Chalapathi Institute of Pharmaceutical Sciences, to train different segments of students and Job seeking youth in systematic enhancement of Employability Skills towards gainful employment for students / Job seekers.
- (b) The Second Party having been into Educational services through its College by name Chalapathi Institute of Pharmaceutical Sciences, submitted a proposal to the first party, upon understanding the requirements and functions of proposed Employability Skill Centres (ESCs). As the second party has intention and requirements as per criterion and agreed to provide services to the first party on the terms and conditions as set forth in this MoA.
- (c) In pursuance thereof, the parties have agreed to enter into this Agreement.

A. PURPOSE:

The purpose of this MoA is to clarify and sort out the roles and responsibilities of both parties in establishing and managing Employability Skill Centres (ESCs) for UG/ PG studying candidates in Various Degree/PG Colleges/University Campuses to enhance employability of students.

Chalapathi Institute of Pharmaceurual Colonnes

(Autonomous)

Chalapathi Nagar, LAM, GUNTUR-341 Page

ROLES AND RESPONSIBILITIES:

B. FIRST PARTY

Responsibilities of APSSDC

- B.1 Shall prepare over all calendar programs and communicate to Second Party;
- B.2 Shall Organize Training Programs for all Under Graduate and Post Graduate students. The programs would be of nature, common core (for all students); and modular (elective in nature) and Community specific modules;
- B.3 Shall appoint required manpower to manage and coordinate Trainings in ESCs;
- B.3 Shall be installing requisite IT infrastructure as listed in Schedule -1 in the Employability Skills centers (ESCs) in the earmarked rooms by The second party;
- B.4 The First Party shall prepare Operational Guidelines for ESC to be followed by both the parties;
- B.5 The First Party will take care of insurance, regular maintenance and consumables items pertaining to Hardware provided.
- B.6 The First Party shall have right on any undefined business and activity that falls under purview of this MOA.

C. SECOND PARTY

- C.1 Shall provide the building space in terms of Two (2) Computer Labs and One (1) E-Class room with a minimum seating capacity of 50 each room space at the College premises to the First Party for Establishing the Employability Skill Center allocated to the Second Party. The second party shall ensure adequate furniture and electrical fixtures in the class rooms and labs;
- C.2 Shall be responsible for ensuring proper physical security of the IT & other electronic Items as per schedule-1. Towards security, the second party shall do necessary arrangements and ensure the security for the items;
- C.3 Shall facilitate trainings for different segments namely students within campus, students from other colleges and job seeking youth and the college shall allow its students to attend programs, take assessments and interviews as per schedule communicated by first party;
- C.4 Shall provide separate Toilets to the boys and girls, who undergone training at the Employability Skill Center;
- C.5 Shall put necessary efforts and ensure maximum participation of students belonging to Scheduled Caste (SC) and Scheduled Tribe (ST) Categories in the college;

Chalanathi Institute of Obarmacoutical Sciences

- C.6 Shall appoint a Centre Coordinator as Single point of contact person (SPOC) for all admin and programme related activities with the Second Party at the Employability Skill Centre for smooth running of the ESC.
- C.7 Shall actively participate in the ESC Programs, communicate feedback from the college and students, suggesting for betterment of the ESC programs towards maximizing reach;
- C.8 Shall arrange for common facilities of housekeeping, security, electrical supply, Drinking and Usage water to the Toilets for the Employability Skill Center students;
- C.9 Shall mark the daily attendance in the suggested mode (manual or bio metric or iris scan or so) by the SPOC of Second Party in coordination with ESC Coordinator.
- C.10 Shall facilitating in collecting the registration fee as communicated by the First Party, from the candidates provided by the Second Party.
- C.11 Shall follow Operational Guidelines of ESCs in maintaining activities in ESCs.

D Responsibilities of Both Parties

The Both Parties agree that:

- D.1 The Parties shall diligently perform their respective obligation under the Arrangement as per the procedure set forth above.
- D.2 Neither Party shall share any Confidential Information with any other party. The sharing of such database by each other will be on trust that it will not be used by either Party for providing any kind of information to any third party.
- D.3 The Parties agree to use the Confidential Information only for the purposes of this Arrangement and only as permitted herein under this MoA.
- D.4. The ESC shall exclusively be used for in program to be assigned by the First Party to Second Party.
 - E Ownership of assets: the ownership of the IT infrastructure/assets will lies with APSSDC whereas the second party, would be the custodian of the installed assets.
 - F Arbitration: In the case of dispute arising upon or in relation to or in connection with the contract between the APSSDC and Second party, which has not been settled amicably, any party can refer the dispute for Arbitration under (Indian) Arbitration and Conciliation Act, 1996. The Arbitration and Conciliation Act, 1996 and any statutory modification or re-enactment thereof, shall apply to these arbitration proceedings.

Chalapathi Institute of Pharmaceutical Sciences


G. Termination of the MOA:

- a) Termination for Default: The first party may, without prejudice to any other remedy for breach of Agreement, by a written notice of default of at least 30 days sent to the second party, terminate the Agreement in whole or in part (provided a cure period of not less than 30 days is given to the second party to rectify the breach):
 - (a) The agreement may be terminated if it is discovered at any stage that the second party has been furnishing false claims or providing misleading information with respect to enrolment of trainees, conduct of training or any other aspect related to programme.
 - (b) If the second party, in the judgment of the first party, is found to be engaged in corrupt, fraudulent, coercive and restrictive or collusive practices in competing for or in executing the Agreement.
 - (c) If the second party commits breach of any condition of the Agreement.
 - (d) If the second party is de-empanelled at any stage during the course of the Agreement.
- Agreement by giving a written notice of at least 30 days to the second party, if the second party becomes bankrupt or otherwise insolvent. In such event, termination will be without compensation to the second party, provided that such termination will not prejudice or affect any right of action or remedy that has accrued or will accrue thereafter to the first party.
- c) Termination for Convenience -The first party, by a written notice of at least 30 days sent to the second party, may terminate the Agreement, in whole or in part, at any time for its convenience. The Notice of Termination shall specify that termination is for the first party's convenience, the extent to which performance of the second party under the Agreement is terminated, and the date upon which such termination becomes effective. Depending on merits of the case the second party may be appropriately compensated for the loss incurred by the Agreement, if any, due to such termination.
- d) Limitation of Liability In no event shall either party be liable for consequential, incidental, indirect, or punitive loss, damage or expenses (including lost profits). The second party shall not be liable to the other

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

5 | Page

- hereunder or in relation hereto (whether in Agreement, tort, strict liability or otherwise) for more than the annual value of the training fees and any incentive paid (including any amounts invoiced but not yet paid) under this Agreement.
- e) Termination by the Client first party may, by not less than thirty (30) days' written notice of termination to the second party, such notice to be given after the occurrence of any of the events, terminate this Agreement, if:
 - a. The second party fails to remedy any breach hereof or any failure in the performance of its obligations hereunder, as specified in a notice of suspension, within thirty (30) days of receipt of such notice of suspension or within such further period as the first party may have subsequently granted in writing;
 - The second party becomes insolvent or bankrupt or enters into any agreement with its creditors for relief of debt or take advantage of any law for the benefit of debtors or goes into liquidation or receivership whether compulsory or voluntary;
 - The second party fails to comply with any final decision reached as a result of arbitration proceedings;
 - d. The second party fails to comply with the decisions of the first party;
 - e. The second party submits to the first party a statement which has a material effect on the rights, obligations or interests of the first party and which the second party knows to be false;
- f) Termination by the second party The second party may, by not less than thirty (30) days' written notice to the first party, such notice to be given after the occurrence of any of the events, terminate this Agreement if:
- g) Upon termination of this Agreement by notice of either Party to the other Party, the second party shall immediately upon dispatch or receipt of such notice, take all necessary steps to bring the Services to a close in a prompt and orderly manner and shall make every reasonable effort to keep expenditures for this purpose to a minimum.
- h) The first party will reserve the right to cancel the MOA and take back all installed and transferred items as per schedule-1 in the circumstances of the second party's non-cooperation to organize ESC programs to its fullest potential.
- i) The First party shall reserve the decision rights on the scheduled items on completion of tenure of the agreement.



H. Representations and Warranties by the Parties

In addition to the above the Parties hereto represent and warrants to other Parties as under:

- a) That it is duly organized and validly existing under the laws of the jurisdiction in which incorporated and has the necessary corporate power and authority under Applicable Laws to carry on its business and or perform its functions.
- b) That this MoA
 - I. is within its powers and has been duly authorized by it; and
 - II. does not conflict in any material respect with any law or regulation or its constitutional documents or any document binding on it and that it has obtained all necessary consents for the performance by it under this MoA.
- c) That all information set forth in this MoA is true and correct and is not misleading in letter and spirit.

I. PERIOD OF VALIDITY:

This MoA shall become effective from the date hereof and shall be in force for a period of three years, unless terminated by mutual consent of the parties.

Each Party shall, however, have the right to terminate this MoA without assigning any reasons by giving prior written notice of 90 (Ninety) days through its authorized signatory. Without prejudice to the above, each Party may terminate this MoA by giving 45 (Forty Five) days notice in the event of breach of any of the terms of this MoA by any of the other Parties, however, such party shall serve a prior notice of its intention to terminate this MoA to the other parties and such event of breach should have remained un resolved/ un rectified within the said notice period of 45 days or such extended period as may be mutually agreed to.

J. NOTICES:

Unless otherwise provided herein, all notices or other communications under or in connection with this MoA shall be in English, will be issued in writing and shall be signed by the authorized representative of the issuing / serving Party and may be sent by personal delivery or post or courier or facsimile to the address, facsimile number given below. Any such notice or other communication will be deemed to be effective if sent by personal delivery, when delivered, if sent by post, three days after being deposited in the post and if sent by courier, two days after being deposited with the courier, and if sent by facsimile, when sent (on receipt of a confirmation to the correct facsimile number).

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

7 | Page

K. COMMUNICATIONS AND PUBLICITY:

The Parties shall consult and agree on all and any intended communications, publications, presentations and documentations relating to this Arrangement/ MoA (jointly the "Communication(s)") in advance prior to the intended release. If a MoA cannot be reached, a Party shall have the right to disclaim endorsement and/or dissociate itself from that Communication(s). No party shall use logo/trade mark etc. of each of the parties without obtaining its prior written concurrence to that effect.

J. IT IS MUTUALLY UNDERSTOOD AND AGREED BY AND BETWEEN THE PARTIES THAT:

MODIFICATION: Modifications within the scope of the instrument shall be made by mutual consent of the parties, by the issuance of a written modification, signed, and dated by all parties, prior to any changes being performed but all rights reserved by First Party can change any point of time needed.

INFORMATION OWNERSHIP: All information provided by First Party shall only be utilized for conducting training and placement assistance and First Party holds no ownership over the content prepared by Second party. First Party will in no way share or distribute any information received with other public or private agencies, organizations, and individuals\

<u>PARTICIPATION IN SIMILAR ACTIVITIES:</u> This instrument in no way restricts First Party from participating in similar activities with other public or private agencies, organizations, and individuals.

NON-FUND OBLIGATING DOCUMENT: This instrument is neither a fiscal nor a funds obligation document.


ESTABLISHMENT OF RESPONSIBILITY: This MoA is not intended to, and not create any right benefit or trust responsibility, substantive or procedural, enforceable at law, by a party against First Party or Second Party.

<u>COMMENCEMENT/EXPIRATION DATE:</u> This instrument is executed as of the date of last signature and is effective up to 3 years after end of service and will automatically expire unless extended.

<u>AUTHORIZED REPRESENTATIVES:</u> By signing below, the individuals signed in this document as representatives of First Party, Second Party are authorized to act in their respective areas for matters related to this MoA.

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

8 | Page





७०|०।००० आध्र प्रदेश ANDHR SL No: | 0279 Date: 29/10 20 21 Rs. 201 sold to Y. V. Asija negul

LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021

D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

M/S. BIOPHORE PHARMACEUTICALS LIMITED COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

accordance with the mutual desire to promote cooperation between the institute CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, Guntur and the Company M/S. BIOPHORE PHARMACEUTICALS LIMITED enter into this fermal statement of collaboration in the form of Memorandum of Understanding (M.O.U.) for the purpose of Academic and Professional exchanges.

Both the institutions have found it mutually beneficial to explore co-operative aptivities for the following purposes.

- 1. Training of B.Pharmacy students every year for a period of one month at BIOPHORE PHARMACEUTICALS LIMITED by assignment of short term Research Projects.
- Collaboration in Research activities between Industry and Institute.
- 3. Exchange of visits between Chalapathi Institute of Pharmaceutical Sciences and Biophore Pharmaceuticals Limited. Professionals /Faculty Members of the institute to their counter part and place.
- 4. Organization of joint Seminars/Training Programmes/Meetings.
- 5. Placement of B.Pharmacy/M.Pharmacy students whenever it is possible.

It is understood that the details of joint activities/conditions for the utilization of results achieved, arrangements for specific visits, exchange and all other form of co-operation will be handled on mutually agreeable terms for each specific case.

mound Si Y.V.Anjaneyulu

Resident Chalapathi Educational Society, Lam, Guntur

1 Ocemato Dr. R. Jagadiah Babu Chalapathi Institute of Pharmaceutical Sci Biophore Pharmaceutical Limited, Hyderabad (Autonomous)

Chalapathi Nagar, LAM, GUNTUR



ಆಂ|ಕ್ರವವೆर्ड आंध्र प्रदेश ANDHRA PRADESH

SL No: [026/ Bate: 29/10) 20 21 Rs. 201 sold 10 y. v. Anjanegulu so seetaramaich audur

LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA

GUNTUR Dt. Cell: 9866368173

OF UNDERSANDING

COLLOBORATION OF INDUSTRY-ACADEMIC INTERACTION

M/S. DELEXCEL PHARMA PRIVATE LIMITED enter into this formal ment of collaboration in the form of Memorandum of Understanding (M.O.U.) for the purpose of Academic and Professional exchanges.

th the institutions have found it mutually beneficial to explore co-operative tivities for the following purposes.

- 1. Training of B.Pharmacy students every year for a period of one month at DelExcel Pharma Private Limited by assignment of short term Research Projects.
- 2. Collaborati
- Exchange of visits between Chalapathi Institute of Pharmaceutical Sciences and DelExcel Pharma Private Limited. Professionals /Faculty Members of the institute to their counter part and place
- Placement of B.Pharmacy/M.Pharmacy students whenever it is possible.
- Based on the infrastructural facilities available at Chalapathi Institute of Pharmaceutical Sciences, Guntur, DelExcel Pharma Private Limited may consider collaborative research projects.
- details of joint activities/conditions for utilization of results achieved, arrangements for specific visits, exchange and all other form of co-operation will be handled on mutually agreeable terms for

natapathi Educational Societ

Lam. GUNTUR 527 034

Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.



ಆಂధ్రోప్రదేశ్ల్ आन्ध्र प्रदेश ANDHRA PRADESH

pusident. Y. V. Anjone you are Lan

MEMORANDUM OF UNDERSTANDING BETWEEN CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR

GOVERNMENT GENERAL HOSPITAL, GUNTUR

COLLABORATION OF PROFESSIONAL -ACADEMIC INTERACTION (CLINICAL INTERNSHIP/HOSPITAL PRACTICES)

In accordance with the Mutual Desire to promote co-operation as per G.O.M.S.NO.398 dated 15-11-2008, Health, Medical and Family Welfare(E1) Department of Government of Andhra Pradesh, between CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES (Sponsored by Chalapathi Educational Society), Chalapathi Nagar, Lam, Guntur-522 034 and GOVERNMENT GENERAL HOSPITAL, GUNTUR (1177 BEDDED TEACHING HOSPITAL) enter into this formal statement of collaboration in the form of Memorandum of Understanding (M.O.U.) for the purpose of residency training/internship of Pharm.D and Pharm.D (Post Baccalaureate) students of Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522034, with the following specific objectives.

30/12/08

SUPERINTENDENT GOVERNMENT GENERAL HOSPITAL Guntur

PRESIDENT

Chalapathi Institute of Pharmaceutical Sciences

D. No: 5-87-70/7/A, 1st Line. Chandremouli Negar, GUNTUR- 522 007

- O1. To Provide patient care in cooperation with patients, and other members of an inter professional health care team based upon sound therapeutic principles and evidence-based data, taking into account relevant legal, ethical, social cultural, economic, and professional issues, emerging technologies, and evolving biomedical, pharmaceutical, social/behavioral/ administrative, and clinical sciences that may have an impact on therapeutic outcomes.
- O2. To Manage and use resources of the health care system, in cooperation with patients, prescribes, other health care providers, and administrative and supportive personnel, to promote health; to provide, assess, and coordinate safe, accurate, and time-sensitive medication distribution; and to improve therapeutic outcomes of medication use.
- 03. To Promote health improvement, wellbeing, and disease prevention in cooperation with patients, communities and other members of an inter professional team of health care providers.
- 04. To demonstrate skills in monitoring of the National Health Programme and schemes oriented to provide preventive and primitive health care services to the community.
- 05. To develop leadership qualities to function effectively as a member of the health team organized to deliver the health and family welfare service in existing socio-economic, political and cultural environment.
- 06. To Communicate effectively with patient and the community

Both the institutions have found it mutually beneficial to explore cooperative activities for the following purposes.

- 01. To provide Internship/residency training in GOVERNMENT GENERAL HOSPITAL, GUNTUR, (1177 BEDDED TEACHING HOSPITAL) for 30 Students of Pharm-D and 10 students Pharm-D (Post Baccalaureate) Programmes of CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, Chalapathi Nagar, Lam, Guntur-522 034 during the course, by posting the students in clinical specialty units like Surgery, Pediatrics, Gynecology and Obstetrics, Psychiatry, DVL and Orthopedics including General Medicine Department.
- 02. To provide Pharmacy practice in the department of Pharmacy for 30 students of Pharm-D and 10 students of Pharm-D (Post Baccalaureate) Programmes of Chalapathi Institute of Pharmaceutical Sciences in **GOVERNMENT GENERAL HOSPITAL**, **GUNTUR** with a minimum carpet area of 30 sq.ft. per student.

SUPERINTENDENT
GOVERNMENT GENERAL HOSPITAL
Guntur

30/12/06

Chalapathi Institute of Pharmaceutical Sciences
Guntur

CHALAPATHI EDUCATIONAL SOCIETY
D. No: 5-87-79/7/A, 1st Line,
Chandramouli Nager, GUNTUR- 522 007

- To spare professional man power to support Pharm-D and Pharm-D (Post Baccalaureate) Programmes of Chalapathi Institute of Pharmaceutical Sciences.
- To expose Pharm-D and Pharm-D (Post Baccalaureate) students of 04. Chalapathi Institute of Pharmaceutical Sciences, to actual pharmacy practice/clinical pharmacy services.
- To extend internship/residency training for period of 12 months for 30 05. students of Pharm-D and 10 students of Pharm-D (Post Baccalaureate) Programmes of Chalapathi Institute of Pharmaceutical Sciences.
- The superintendent of Government General Hospital, Guntur, shall maintain a register of Internship Pharmacy students of Chalapathi Institute of Pharmaceutical sciences as per Pharmacy Council of India regulations.
- 07. An amount of Rs.25,000/- (Rupees twenty five thousand only) shall be collected as fees for residency training/Internship from the Pharm-D and Pharm-D (Post Baccalaureate) students of Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur, per annum/per student which shall be deposited with the Hospital Development Society of Government General Hospital Guntur.

It is understood that the details of joint activities/conditions for the utilization of results achieved, arrangements for specific visits, exchange and all other form of co-operation will be handled on mutually agreeable terms for each specific case.

SUPERINTENDENT GOVERNMENT GENERAL HOSPITAL

Guntur

Chalapathi Institute of Pharmaceutical Sciences

Chalapathi Educational Society Chalapathi Nagar, Lam, GUNTUR-522 034



SL No: |0266 02 0:29 /6 20 2 Rs: 201

For Whom

LICENCED STAMP VENDOR L.No: 07-14-010/2014

R.L. No: 07-14-005/2021

D.No: 19-71, TADIKONDA

(A Unit of Shrimanta Shankar Academy)

Between



Girijananda Chowdhury Institute of Pharmaceutical Sciences NH - 37, Azara, Hathkhowapara, Guwahati, Assam: 781 017



(Autonomous)

Chalapathi Institute of Pharmaceutical Sciences (CLPT) Coxolo

(Autonomous) Chalapathi Nagar, Lam, Guntur, Andhra Pradesh-522 034

Dated 29th December 2018

PRINCIPAL Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.

This Memorandum of Understanding (hereafter MoU) is signed by the between:

Girijananda Chowdhury Institute of Pharmaceutical Sciences, Guwahati, Assam, India (hereafter GIPS), a self financing Pharmacy Institute established under the aegis of Shrimanta Shankar Academy (SSA) Society, Guwahati, Assam, India to promote education and research in the area of Pharmaceutical and allied sciences.

and

Chalapathi Institute of Pharmaceutical Sciences (Autonomous), Guntur, Andhra Pradesh, India (hereafter CLPT), a self financing Pharmacy institution established by Sri Y.V.Anjaneyulu, Chairman of Chalapathi Educational Society.

The aforesaid institutions are hereafter referred to individually as institute and collectively as Institutes.

01. PREAMBLE:

WHEREAS, GIPS and CLPT have areas of common interests in promoting and developing entrepreneurs in Pharmaceutical, healthcare and allied sciences, considerable advantages may be gained from their pursuit on a collaborative basis in the field of academics, training and research.

NOW THEREFORE, GIPS and CLPT have decided to enter into this MoU which defines the framework for the cooperation of these two institutions set out in the following sections.

02. OBJECTIVES :

Both institutes agree to develop following collaborative activities in the areas of academics, training and research activities on the basis of equality and reciprocity. The two institutes shall seek to promote:

A. Faculty and staff exchange:

- i. To exchange of faculty members and staffs for conducting lectures, consultancy studies, adjunct teaching, expert lectures, seminars, cosupervision of students projects.
- ii. To attach faculty members and other staffs for curriculum development and review, upgrading of teaching and research skill.
- iii. To participate in seminars, symposiums and other types of discussion.
- iv. To conducting short-term courses jointly.

Chalapathi Institute of Pharmaceutical Sciences (Autonomous) Chalapathi Nagar, LAM, GUNTUR-34

B. Research and development:

- i. To collaborate in research and development in the field of mutual interest.
- ii. To organize and undertake joint research projects.
- iii. To identify opportunities for transfer of technologies, commercialization of research findings.
- iv. To protect intellectual property rights of both institutes and filing joint patent application wherever applicable.
- v. To promote joint publications.
- vi. To share publications, research data, library information.

C. Other areas:

- i. To provide cultural and intellectual enrichment opportunities for staffs and students of both institutes.
- ii. To use laboratories and other facilities in specific cases for a predetermined period of time.
- iii. To organize joint seminars, conferences, training programs and invites each other's faculties and students to participate therein.
- iv. To facilitate and assist placement of each other's graduates.
- v. Any other appropriate mode of interaction agreed upon between signing institutes.

03. COORDINATION:

Each institution shall appoint one member of its faculty as Coordinator. The coordinators may meet periodically as and when necessary to review progress in the implementation of activities related to the areas of collaboration, define new areas and programmes of collaboration as well as discuss matters related to this MoU.

04. FUNDING ARRANGEMENT:

To implement the collaborative activities envisaged under this representatives of the institute may meet periodically to negotiate and conclude specific project agreements and programmes of cooperation, including the terms for their financing, with each other and with other institutes provided that neither institute shall have the power to bind the other institute without the other institute's consent in writing. Financial commitment from each institute for a collaborative activity shall be agreed upon separately by both institutes prior to the event.

05. INTELLECTUAL PROPERTY, INVENTIONS AND INNOVATIONS

- 5.1 Ownership of any intellectual property (including but not limited to confidential information, know-how, patents, copyrights, design rights, rights relating to computer software, and any other industrial or intellectual property rights) developed jointly during the course of this MoU shall be vested in both institutes to this Memorandum. Both institutes shall have the joint right to determine the commercial exploitation and disposition of such intellectual property, and both institutes shall make joint applications for the registration of the same. Before any registration or commercialization of any intellectual property takes place, the institutes agree to reach a separate agreement covering issues such as exploitation rights and revenue sharing.
- 5.2 The terms with respect to title to and exploitation of intellectual property, inventions and innovations will be negotiated on a project-byproject basis in the specific project agreements and programs of cooperation.
- 5.3 Nothing in this MoU shall be construed as a license or transfer or an obligation to enter into any further agreement with respect to any intellectual property currently licensed to or belonging to either Institute.
- 5.4 All intellectual property held by a Institute prior to entering into this MoU or disclosed or introduced in connection with this MoU and all materials in which such intellectual property is held, disclosed or introduced shall remain the property of the Institute introducing or disclosing it.

PUBLICATION OF ARTICLES 06.

- 6.1 Each Institute may, with the written consent of the other Institute, such consent not to be unreasonably withheld, publish the findings of the collaborative activities of the Institutes in the form of an article in a journal, newspaper or other magazine, provided that where an application for registration of a trademark, service mark or design, or an application for a patent, will be made, such an article shall not be published for a period of up to ninety (90) days for the said application to be made.
- 6.2 A copy of the article to be published shall be provided to the Institute whose written consent is required hereunder prior to publication of the same for that Institute's perusal and written consent.

29. 12. 201 Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.

CONFIDENTIALITY 07.

- 7.1 Neither Institute shall use the name or logo of the other Institute for any purpose whether in relation to any advertisement or other form of publicity without obtaining the prior written consent of the other Institute.
- 7.2 Notwithstanding the generality of the above, the Institutes may notify third parties of the fact that this MoU is in effect.
- 7.3 All information furnished in relation to this MoU by one Institute to the other, which is clearly identified as proprietary or confidential at the time of disclosure, will be kept confidential by the receiving Institute, and will not be disclosed to any third parties otherwise than to carry out the provisions of this MoU, unless agreed in writing between the Institutes.
- 7.4 The provisions of Clause 7.3 above will not apply to information in the public domain; information in the possession of the receiving Institute prior to the disclosure of the information; information which is independently developed by the receiving Institute; information required to be released by law; and information which is rightfully received by the receiving Institute from third parties without any breach of confidentiality obligations.

AMENDMENTS 08.

This MOU may be amended and supplemented in writing at any time by the mutual consent of the Institutes in writing.

09. TERM OF MOU

- 9.1 This MoU shall commence on the Effective Date and shall remain in force for a period of five (5) years. Thereafter, this MoU may be extended for any further period upon written notice by either Institute to the other at least six (6) months before the expiry of the initial term and upon written acceptance by the other Institute.
- 9.2 Either Institute may terminate this MoU by written notice to the other Institute of its desire to terminate one (1) year prior to the desired date of termination.
- 9.3 The termination of this MoU shall not affect the implementation of the projects or programmes established under it prior to such termination.

10. DISPUTE RESOLUTION

Any disputes arising under or in connection with this MoU which cannot be resolved by amicable discussions between the Institutes shall be referred to the Chair of the respective Institutes or their nominees for resolution, or may be submitted to such alternative dispute resolution mechanism as may be agreed in writing between the Institutes.

(Autonomous)

Chalapathi Nagar, Litill, GUNTUR-34.

NON-BINDING NATURE OF THIS MOU 11.

- 11.1 Despite the statements and obligations expressed herein and save for this MoU is a non-binding expression of the current intentions of the Institutes, and neither Institute will incur nor be bound to any legal obligations or expense hereunder to the other Institute until and unless definitive agreements have been negotiated, approved by the necessary management levels of each Institute and executed and delivered by authorized representatives of both Institutes.
- 11.2 Clauses shall survive the expiry or termination of this MoU and shall be legally enforceable in accordance with their terms in any court of competent jurisdiction.

12 ADHERENCE TO LAWS

- 12.1 This MoU shall be governed by and construed in accordance with the laws of the Republic of India and the laws of Philippines.
- 12.2 Participating faculties, staff and students involved in any activities under this Memorandum must adhere to the law of the host countries and rules and regulations of the institutions.

Girijananda Chowdhury Institute of Pharmaceutical Science, Guwahati, Assam, INDIA and Chalapathi Institute of Pharmaceutical Sciences (Autonomous), Guntur, Andhra Pradesh, INDIA welcomes the establishment of this Memorandum for cooperation and jointly agree to the provisions set out above on this 29th day of December 2018.

Prof.(Dr.) Gouranga Das

Signed for and on behalf of Girijananda Chowdhury Institute of Pharmaceutical Sciences Guwahati, Assam, India

> Prof. (Dr.) Gouranga Das Principal Girijananda Chowdhury Institute of Pharmaceutical Science Azara Guwahati-17

(Prof.Rama Rao Nadendia)

Signed for and on behalf of Chalapathi Institute of Pharmaceutical Sciences (Autonomous),

Lam, Guntur, Andhra Pradesh, India

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences (Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34

PRINCIPAL

Chalapathi Institute of Pharmaceutical Sciences

(Autonomous)



ಆಂದ್ರ್(ప್ರವೆ है , आंध्र प्रदेश ANDHRA PRADESH Sold to Y. V. Artianeyella 2/0 entaranaidh, autir.

Institute of Phormacutical Sciences

whan RE.

CONDA MOHAN REDDY

LICENCED STAMP VENDOR L.No: 07-14-010/2014

R.L. No: 07-14-005/2021 D.No: 19-71, DEIKONDA

MEMORANDUM OF UNDERSTANDING

Between

IKYA GLOBAL Education

The agreement is made on 06th December 2018

Technovations Pvt. Ltd., a company incorporated under the law of India represented by Pedel Rajeev K (Here after called as IKYA EDU) located at Suite 503, 5th Floor, HMDA Mythrivanam, Ameerpet, Hyderabad - 500038, Andhra Pradesh.

AND

For Whom

Chalapathi institute of Pharmaceutical Sciences, Lam, Guntur is a premier institute established by Chalapathi Education Society, represented by Sri.Y.V.Anjaneyulu, President, Champathi Educational Society and Prof. Rama Rao Nadendla, Principal, Chalapathi Institute of Pharmaceutical Sciences.

Memorandum of Understanding (MOU) recitals as agreed below:

- 1) IKYA Global EDU has agreed upon to deliver "Industry Ready Graduate Training Programs" for your pharmacy students, duly considering the requirements of the industry. These training modules will equip the students of your college with needed skill sets for knowledge enhancement in on/off campus interviews.
-) We will provide support in the below mentioned modules and we would support you with respect to training and awareness along with some placement connections. Based upon interest and requirement, college can be chosen upon below modules and campus recruitment training with assessment tests, if any. The following are the modules for college training, workshops and seminars.
 - **Pharmacovigilance**
 - Medical Transcription/Coding
 - Medical Billing
 - Clinical Data Management (CDM)
 - Clinical Research
 - Statistical Analysis System (SAS) Campus Recruitment Training (CStalapathi Institute of Pharmaceutical Sciences

(Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.

PRINCIPAL





- The needed infrastructure shall be arranged by college management like Hall/Class room with board, LCD with Screen and public addressable system during the support given by IKYA.
- 4) With respect to placement assistance, IKYA will recommend one of our partner network company "Avontix India Private Limited" to recruit candidates based upon meeting the specific interview criteria of client and requirement in the month of January - February every year.
- 5) The training and awareness programs support from IKYA will be in commercial basis which will be given in separate/prior proposal format to college.
- 6) This MOU is valid for 2 years and signing of this MOU does not involve any commercial aspects.

To initiate the programs delivery and association - This MOU must be signed and accordingly program will be initiated.

Chalapathi Institute of Pharmaceutical KYA Global EDU, Hyderabad. Sciences, Lam, Guntur

Signature:

Signed By: Sri. Y.V. Anjaneyulu

Designation: President, Chalapathi

Educational Society.

Date:

Signature: K. Palle Raja:

Signed By: Mr. Peddi Rajeev K

Designation: Territory Head

Date: 06/12/2018

Chalapathi Institute of Pharmaceutical Science. (Autonomous)

Chalapathi Nagar, LAM, GUNTUR-34.



ఆంగ్రామదేశ్ आध्र प्रदेश ANDHRA PRADESM

SL No: 10339 Date: | | | 2021 Rs: 206 Y.V. Asjaneyelle 8/0 letaramaiah. Crutur whom Chafapathi Institute of Pharmacutical Sciences

slaw RK LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

MEMORANDUM OF UNDERSTANDING BETWEEN

CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND

M/s. KELVIN LABS

COLLABORATION OF INDUSTRY-ACADEMIC INTERACTION

accordance with the Mutual Desire to promote co-operation between the institute CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, Guntur and the Company M/ KELVIN LABS enter into this formal statement of collaboration in the form of Memorandum of Understanding (M.O.U.) for the purpose of Academic and Professional exchanges. Both the institutions have found it mutually beneficial to explore co-operative activities for the following purposes,

- Training of 10 B.Pharmacy students every year for a period of one month at KELVIN LABS by assignment short term Research Projects. 1)
- 2) Collaboration in Research activities between Industry and Institute.
- Exchange of visits between Chalapathi Institute of Pharmaceutical Sciences and Kelvin Labs Professionals/ Faculty Members of the institute to their counter part and place. 3)
- 4) Organization of joint Seminars/Training Programmes/Meetings
 - 5) Placement of B.Pharmacy/M.Pharmacy students wherever it is possible.
- understood that the details of joint activities/conditions for the utilization of results achieved, arrangements for specific visits, exchange and all other form of co-operation will be

K.SURYA KUMARI PRINCIPAL

K.SURYA KUMARI

Managing Parther path Institute of Pharmaceutical Science

(Auton Challapath) Institute PRESIDENT

(Auton Chatapathi Institute of Pharmaceutical Sciences KELVIN Labs, Hyderabad. Chalapathi Nagar, LAM, Chalapathi Nagar, Lam, Guntur-34



ಆಂಥ್ರ್ರವರೆ श प्रदेश ANDHRA PRADESH

SL No: 1033 7 pate: 1 11 20 21 Ra 20/ sold to Y.v. Anjaneyeller 810 Scetaramaiah, Culul For Whom Chalapathi Institute of Pharmaculical Sciences

(UNIVERSITY-INSTITUTION INTERACTION)
MEMORANDUM OF UNDERSTANDING BETWEEN KRISHNA UNIVERSITY, MACHILIPATNAM

AND CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR

FOR COLLOBORATION OF ACADEMIC / RESEARCH INTERACTION

In accordance with the mutual desire to promote cooperation between Krishna University, Machilipatnam and Chalapathi Institute of Pharmaceutical Sciences, Lam, Guntur, both the University and Institution enter into this formal statement of collaboration in the form of Memorandum of Understanding (MOU) for the purpose of Academic / Research interaction.

Both the institutions have found it mutually beneficial to explore cooperative activities for the following purposes:

- 1. Collaboration in Research activities between Chalapathi Institute Pharmaceutical Sciences Krishna and University. of Machilipatnam.
- 2. Exchange of Professionals/Faculty members visits between Krishna University, Machilipatnam and Chalapathi Institute of Pharmaceutical Sciences, Guntur.
- 3. Organization of Joint Seminars/Training Programmes/Meetings.
- 4. Extra Mural Research facility to the faculty members of Chalapathi Institute of Pharmaceutical Sciences.

It is understood that the details of joint activities/conditions for utilization of results achieved, arrangements for specific visits, exchange and all other form of cooperation will be handled on mutually agreeable terms for each specific case.

POOMO

Sri Y.V.Anjaneyulu

President

PRINCIPAL Chalapathi Institute of Pharmaceutical Sciences Strait

Erishna University

KONDA MOHAN REDDY

LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

11/4/2009

Chalapathi Educational Sagisti Nagar, LAM, GUNTUR 34 chilipatnam.



ఆంగ్లిడ్డ్ ప్రైవేశ్ आन्ध्र प्रदेश ANDHRA PRADESH

For Whom:

Ganga Raju : lo Ranga Raju ... VIJAYAWADA-10.
LIC No: 19/2013, PL. Mo: 24/2013
ila Mutraclutical . wijayawala valid Upto. B. 1-01-20141031-12-201

STAMP VENBOR PROTAMATA.

D.No: 66-1-14, Sivalayam Street

ell. 9951414443

CONFIDENTIALITY AND NON-DISCLOSURE AGREEMENT

This Agreement is made on December 15, 2015 between Laila Nutraceuticals and Chalapathi Institute of Pharmaceutical Sciences.

Laila Nutraceuticals

40-15-14, Brindavan Colony, Labbipet, Vijayawada-520010, Andhra Pradesh, India (Herein referred to as "Laila")

AND

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522034 (Hereiin referred to as Chalapathi)

(Hereinafter referred to individually as a "Party" and collectively as the "Parties")

Page 1 of 7

Institute of Pharmaceutical Sciences (Autonomous) Chalapathi Nagar, LAM, GUNTUR-34.



WHEREAS, Laila Nutraceuticals is a leading Research, development and manufacturing company developing specialty herbal ingredients for the nutrition, pharmaceutical, dietary supplement, cosmetic and healthcare industry (hereinafter referred to as "Laila" which expression shall, unless excluded by or repugnant to the context, be deemed to include its principals including affiliates & subsidiaries, successors-in-interest and assigns).

WHEREAS, Chalapathi Institute of Pharmaceutical Sciences sponsored by Chalapathi Educational Society is a premier education and research institute imparting Pharmaceutical Education and Research. The institute is Accredeted with "A" grade (Excellent) by NAAC, recognized by UGC under section 2f and 12(B) and recognized by DSIR for research. (hereinafter referred to as "Chalapathi" which expression shall, unless excluded by or repugnant to the context, be deemed to include its principals including affiliates & subsidiaries, successors-in-interest and assigns)

WHEREAS, Subject to the terms of this agreement, Laila wishes to assist the Chalapathi's students in coordination with the faculty by facilitating better understanding of the Industry requirements, facilitate few student projects either at Laila's R&D or the Chalapathi's research labs and conduct formulation and/or *In Vitro* and/or *In vivo* experiments in either of the facilities. In this research process Laila may use its ingredients (test items) /proprietary ingredients, technologies, animal models and disease models. The students/research fellows and staff of the institute may become aware or may need to know some of the information regarding Laila's technology, test items, test results, animal models, disease models etc. Hence Laila wishes to disclose to Chalapathi certain Confidential Information as required to train/conduct the said experiments. For the sake of clarity, all information on test items, test results, proprietary disease models will remain the confidential property of Laila and the Chalapathi shall take all measures to ensure that the students and faculty shall maintain such information confidential.

WHEREAS, Chalapathi agrees to protect the confidentiality of all information it receives from Laila through this Agreement.

THEREFORE, in consideration of mutual promises and other valuable information exchanged and intended to be legally bound, the Parties hereby agree and contract as follows;

DEFINITIONS

1.1 "Affiliates" means with respect to each Party, the legal entities that are controlled by, or under common control with, such Party.

B

Page 2 of 7

1.2 "Confidential Information" shall be deemed to include (without limitation) (a) the following types of information and other information of a similar nature, whether or not so declared in writing: discoveries, techniques, know-how, ideas and concepts, formulations, molecules, structures, drug delivery regimes, designs, drawings, specifications, techniques, models, prototypes, data, documentation, manuals, diagrams, flow charts, schematics, research, process, procedures, functions, and all analyses, compilations, forecasts, studies or other documents, customer names and other information related to customers price lists, pricing policies and financial information, any and all related herbal materials, inventions, practices, methods, knowledge, skill experience, test data (including pharmacological, toxicological and clinical test data), analytical and quality control data and manufacturing and patent data or descriptions; (b) any similar information disclosed to the Receiving Party or its employees, students, research fellows prior to the execution of this Agreement; (c) any material transferred from the disclosing party to the receiving party along with the relevant proprietary information; and (d) any data (including in-vitro, pharmacological, toxicological, clinical, formulation test data) generated by the receiving party on the material transferred by the disclosing party or any data generated on material developed using the disclosing party information.

The term "Confidential Information" shall include any and all information and other materials disclosed, furnished, communicated, perceived or supplied by Laila to Chalapathi by virtue of Chalapathi's employees/consultants/students/research fellows visiting, witnessing and/or observing the facilities, laboratories or factory of Laila and /or its Affiliate Company and/or associates could be reasonably assumed to be confidential.

Any information disclosed by Laila will be considered Confidential Information of Laila by Chalapathi whether or not such information is designated as "Confidential" or "Proprietary".

- 1.3 "Disclosing Party" means the Party, Laila, or its employees, director, officers, consultants, financial advisor, agent or Affiliates (its "Representatives") that disclose Confidential Information to Chalapathi (Recipient).
- 1.4 "Disclosure Period" means the period during which either Party may be disclosing Confidential Information to the other Party. The disclosure period shall commence from the effective date set forth above, and shall expire 5 (five) years after such date, unless terminated in writing by mutual agreement of the parties or upon the request of either party in writing. At the end of the "Disclosure Period", the agreement shall be automatically renewed for a period of two years unless and otherwise terminated by either party in writing with a twelve month notice period for such termination.

(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

Page 3 of 7



- 1.5 "Recipient" means the Party, INSTITUTE, its Representatives, employees, students, research fellows who receive Confidential Information from Laila (Disclosing Party).
- 1.6 "Exempt Information" means information that the Recipient can demonstrate by written records (a) is not in violation of Disclosing Party's Intellectual property rights (b) was in its possession prior to the time of disclosure; and (c) is or becomes public knowledge through no fault, omission, or other act of the Receiving Party.
- 1.7 "Permitted User" means an individual who (1) (a) is the Recipient's Representative, director, employee, students, research fellows or (b) is party to an effective confidentiality agreement with Recipient which is consistent with the terms of this Agreement; and (2) has a need-to-know the Confidential Information in connection with the project.

2. REQUIRED CONFIDENTIALITY

- 2.1 Chalapathi and its Representatives will treat the Confidential Information as strictly confidential and proprietary, and will safeguard the confidential and proprietary nature with at least the same degree of care as it holds its own confidential or proprietary information.
- 2.2 Recipient may use the Confidential Information only in connection with the Project, and for no other purpose whatsoever. Recipient will not use the Confidential Information for the personal benefit of itself or a Permitted User, or for the benefit of any third party.
- 2.3 Recipient will not disclose (directly or indirectly) any Confidential Information to, or permit it to be accessed by, any person except a Permitted User. Recipient will cause any Permitted User to whom Confidential Information is disclosed to abide by the confidentiality provisions of this Agreement. On a case-by-case basis, either Party may waive the restrictions of this Section 2.3 to provide for specific disclosures to specific third parties; provided, however, that such waiver must be in writing signed by the Disclosing Party and such third party must execute a confidentiality agreement with the Disclosing Party, which is consistent with the terms of this Agreement and which would prohibit disclosure under the terms of this agreement.
- 2.4 If Recipient is requested to disclose the Confidential Information or the substance of this Agreement in connection with a legal proceeding to comply with a requirement under the law, Recipient will give the Disclosing Party prompt notice of such request so

Page 4 of 7



that the Disclosing Party may seek an appropriate protective order or other remedy, or waive compliance with the relevant provisions of this Agreement. If the Disclosing Party seeks a protective order or other remedy, Recipient, at Disclosing Party's expense, will cooperate with and assist Disclosing Party in such efforts. If the Disclosing Party fails to obtain a protective order or waives compliance with the relevant provisions of this Agreement, Recipient will disclose only that portion of Confidential Information that Laila's legal counsel determines it is required to disclose, or which is ordered to be disclosed by a tribunal or court of competent jurisdiction.

- 2.5 At the end of the Disclosure Period or upon completion of the Project, whichever is earlier, receiving party shall use best efforts to promptly return all confidential information of other party (including all copies in whatever medium provided to, or made by, any permitted user). At the end of disclosure period and/or termination of the agreement the institute or student shall not use any of Laila's technologies for any other purpose.
- 2.6 Recipient agrees that it shall not directly or indirectly modify, reverse engineer, decompile, create or recreate other works from or disassemble any Confidential Information unless permitted in writing by the Disclosing Party. This cause shall survive the termination of confidentiality and/or this agreement.
- 2.7 The Chalapathi Institute shall in good faith offer the right of first refusal to Laila on any inventions or technologies developed in the areas of interest of Laila or in the areas where Laila has assisted the students with projects. The Chalapathi institute shall allow sufficient time for Laila to assess and evaluate the technology or invention and its commercial feasibility before making an offer. The Chalapathi institute or student shall not make the project related information or documents available in public domain, online medium, public or private networks, social platforms/networks etc. The Chalapathi institute or student shall seek prior permission from Laila for publishing the work done in collaboration with Laila or using technologies of Laila and shall duly acknowledge Laila's support in the project.

3. GENERAL PROVISIONS

3.1 The Agreement shall be effective from the date of signing of the last authorized signatory. The Agreement shall remain in force for a period of five (5) years from the effective date, and automatically renewed thereafter for a period of two years. Either

Page 5 of 7



party may terminate the agreement after the five year period with a written notice of twelve months.

- 3.2 The Parties represent and warrant to each other that each has the legal power and authority to enter into this Agreement and to disclose the Confidential Information.
- 3.3 Neither this Agreement, nor either Party's performance under it, will (a) transfer to the Recipient, or create in the Recipient, any proprietary right, title, interest or claim in or to any of the Disclosing Party's Confidential Information; (b) obligate either Party to enter into any other agreement or undertaking of any nature whatsoever with the other Party; (c) prohibit either Party from entering into any other agreement with any other party, if doing so will not violate such Party's obligations hereunder; or (d) be construed as granting a license to the Confidential Information to either Party.
- 3.4 This Agreement sets forth the entire understanding between the Parties as to the subject matter, and supersedes all prior agreements and understandings relating to such subject matter.
- 3.5 This Agreement shall be governed by, and construed and enforced in accordance with the laws of India. The jurisdiction on any matters relating to this agreement will be exercised only and exclusively by the Court at Vijayawada, Andhra Pradesh, India.
- 3.6 The Parties acknowledge that except as expressly set forth herein, (a) neither Party has made any promise to the other, express or implied, upon which either is entitled to rely in any way; and (b) the Parties specifically waive and disclaim any reliance, dependence or action based on any written or verbal statement or promise made by either Party to the other.
- 3.7 Neither the rights nor the obligations of either Party may be assigned or delegated, in whole or in part, without the prior written consent of the other Party. Any such assignment or delegation shall be null and void and of no effect.
- 3.8 This Agreement may be executed by facsimile and/or in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
- 3.9 If any term of this Agreement or the application thereof shall be deemed invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term of this Agreement shall be valid and enforced to the fullest extent permitted by law.

Page 6 of 7

3.10 All obligations of confidentiality except clause 2.6 shall terminate after six (6) years from the termination date of the confidentiality agreement.

The failure of either Party to insist upon the strict observation or performance of any provision of this Agreement, or to exercise any right or remedy shall not impair or waive any such right or remedy in the future. Every right and remedy given by this Agreement to the Parties may be exercised from time to time as often as appropriate.

IN WITNESS WHEREOF the Parties hereto have caused their duly authorized representatives to set their hands hereunder the December 15, 2015.

Signatures:

Name: Mr. Kiran Bhupathiraju

Designation: Chief Executive Officer

Laila Nutraceuticals

Date: 15-12-2015

Witness:

Name: A.V. Krishna Raju

A. V. W. Peige

Date: 15-12-2015

Name: Prof. RAMA RAO NADENDLA Designation:Professor and Principal,

Chalapathi Institute of Pharmaceutical PRINCIPAL

Sciences, Guntuchalapathi Institute of Pharmaceutical Sciences

(Autonomous) Chalapathi Nagar, LAM, GUNTUR-34.

Witness:

Date: 15-12-2015



ಆಂಧ್ರವ್ಷವೆ आंध्र प्रदेश ANDHRA PRADESH

solo to y.v. Anjaneyulu e/o Scetaramaiah, aulw. For Whom Chalapathi Institute of Pharmaculical ecientes.

LICENCED STAMP VENDOR L.No: 07-14-010/2014 R.L. No: 07-14-005/2021 D No: 19-71, TADIKONDA

GUNTUR Dt. Cell: 9866368173

BETWEEN

CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, GUNTUR

LALITHA SUPERSPECIALITY HOSPITAL (Private) Limited, GUNTUR COLLABORATION OF PROFESSIONAL -ACADEMIC INTERACTION

In accordance with the Mutual Desire to promote co-operation between CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, Guntur-522 034 and THE LALITHA SUPERSPECIALITY HOSPITAL (Private) Limited, GUNTUR-522 001 (300 BEDDED HOSPITAL) enter into this formal statement of collaboration in the form of Memorandum of Understanding (M.O.U.) for the purpose of Academic and Professional exchanges with the following specific objectives.

- To Provide patient care in cooperation with patients, prescribes, and other members of an inter professional health care team based upon sound therapeutic principles and evidence-based data, taking into account relevant legal, ethical, social cultural, economic, and professional issues, emerging technologies, and evolving biomedical, pharmaceutical, social/behavioral/administrative, and clinical sciences that may impact therapeutic outcomes.
- 02. To Manage and use resources of the health care system, in cooperation with patients, prescribes, other health care providers, and administrative and supportive personnel, to promote health; to provide, assess, and coordinate safe, accurate, and time-sensitive medication distribution; and to improve therapeutic outcomes of medication use.
- 03. To Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an inter professional team of health care
- providers.

 To demonstrate skills in monitoring of the National Health
 Programme and schemes oriented to provide preventive and 04 primitive health care services to the community.
- 05. To develop leadership qualities to function effectively as a member of the health team organized to deliver the health and family welfare service in existing socio-economic, political and cultural environment.
- To Communicate effectively with patient and the community 06.

Both the institutions have found it mutually beneficial to explore cooperative activities for the following purposes.

- 01. To provide Internship/residency training in LALITHA SUPERSPECIALITY HOSPITAL (Private) Limited, GUNTUR-522 001, (300 BEDDED HOSPITAL) for 30 Students of Pharm-D programme and 10 students Pharm-D (Post Baccalaureate) of CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES, Guntur during the course, by posting the students in specialty units.
- 02. To provide Pharmacy practice department for 40 students of Pharm-D and Pharm-D (Post Baccalaureate) Programme of Chalapathi Institute of Pharmaceutical Sciences in Lalitha Superspeciality Hospital (Private) Limited, Guntur-522 001 with a minimum carpet area of 30 sq.ft. per student.
- 03. To spare professional man power to support Pharm-D programme of Chalapathi Institute of Pharmaceutical Sciences.
- 04. To expose Pharm-D programme students of Chalapathi Institute of Pharmaceutical Sciences, to actual pharmacy practice/clinical pharmacy services.
- 05. To extend internship/residency training for period of 12 months for 30 students of Pharm-D and 10 students of Pharm-D (Post Baccalaureate) Programme of Chalapathi Institute of Pharmaceutical Sciences.

It is understood that the details of joint activities/conditions for the utilization of results achieved, arrangements for specific visits, exchange and all other form of co-operation will be handled on mutually agreeable terms for each specific case.

Chalkman
Lalitha Superspeciality Hospital (Private) Limited
Guntur-522 001

Chalapathi Institute of Pharmaceutical Sciences
Guntur-522 024

MD.,D.M. (Cardiology)

Regd, No. 38629



မ**ု** ပုံသို့ သို့ အားမှ प्रदेश ANDHRA PRADESH SI.No: (767) Dt. 26/9/20/8 Rs. (မော်

For Whom: PSoberiversity of Maryland Eastern Shore, Maryland,

Alapati Sridhar Rao

L.No: 07-16-030/2011 R.L. No: 07-16-012/2017

Geil: 9491478807

Chalapathi Institute of Pharmaceutical Sciences, India

The University of Maryland Eastern Shore (UMES),a constituent institution of higher education in the University System of Maryland, and an agency of the State of Maryland, located in the city of Princess Anne, MD 21803, United States of America and represented by its President Dr. Juliette Bell on one side, and Chalapathi Institute of Pharmaceutical Sciences (CIPS), represented by its President Dr. Sri. Y. V. Anjaneyulu and who is authorized to represent the CIPS, on the other, agreed to sign the following agreement.

Considering

- 1. The mission of the Chalapathi Institute of Pharmaceutical Sciences (CIPS) is to inculcate excellence in various fields of pharmacy, mold the institution as centre of excellence in terms of academics and advanced research. The CIPS is committed to impart quality pharmacy education and research to meet global standards.
- 2. The University of Maryland Eastern Shore (UMES) School of Pharmacy and Health Professions is dedicated to developing exemplary professionals and scholars who are committed to patient-centered care, lifelong learning, discovery, and service for diverse communities of the Delmarva Peninsula, the State of Maryland, and around the world.
- 3. That University of Maryland Eastern Shore and CIPS, recognize the value of cultural and educational exchanges that can be achieved between both institutions, have agreed to conclude this Agreement framework for mutual cooperation, subject to the following articles apath institute of flamaceutical sciences.

(Autonomous)

Agree:

Article 1.

The parties agree to implement activities designed to jointly develop academic, scientific and cultural programs, in compliance with their respective objectives and institutional purposes.

Article 2.

The parties commit themselves to articulate a collaborative system in order to promote:

- Strengthening of institutional relations.
- Collaboration between their faculty and administrators.
- Implementation of actions and development of programs for the training and improvement of students and faculty.
- Student and faculty mobility
- The development of scientific research, innovation and technology transfer.
- Elaboration of proposals for strategic development of both institutions and their local environments.

Article 3.

The different fields of cooperation as well as terms, conditions and procedures for executing each one of the projects to be implemented, will be fixed through specific agreements between the parties which shall be annexed to this agreement.

Article 4.

Specific work programs mentioned in the preceding clause will have to describe accurately the tasks to be implemented, as well as the issues and documents defining the objectives and milestones of such programs, which will be established under the principle of reciprocity of rights and obligations of both institutions.

Article 5.

The results achieved through works done under this agreement, will be common property of both universities and they may be published jointly or separately by the parties, indicating the origin and authorship.

Article 6.

Each specific collaborative agreement established according to the third clause, shall stipulate that the staff of each institution commissioned to carry out the activities of the agreement, should continue to be under the direct supervision of their respective institutions regardless of whether the staff provide their services outside of their own institution or at any other facility where the work has been commissioned.

Article 7.

All programs and activities under this Agreement are subject to the availability of funds and approval of the representatives of both institutions, and do not require institutions to make expenditures or provide funding for these activities.

Article 8.

The term of this agreement shall be from the date it is completely processed and approved the decree that formalizes the agreement and will be valid for a period of four (4) years. This agreement will be renewed for equal periods, and may be rescinded before its expiry at the request of either party with advance written notice to the other of at least thirty (30) days.

There are two signed copies of this agreement in English and each party to the agreement will retain one copy.

CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES

Sri. Y. V. Anjaheyulu President Chalapathi Educational Society President Chalapathi Nagar, Lam, GUNTUR-522 034.

Date: 15. 06. 2016

FACULTY OF PHARMACEUTICAL SCIENCES

Rama Rao Nadendia, M. Pharma, Ph.D., FIC Principal and Dean institute of Pharmacountry Actions.
Chalapathi Nagar, LAM, GUNTUR-34

Date: 15.06.2016

UNIVERSITY OF MARYLAND EASTERN SHORE

Juliette B. Bell, Ph.D.

Lowalo

Date: 1/24/16

President

SCHOOL OF PHARMACY AND HEALTH PROFESSIONS

Rondall E. Allen, B.S., Pharm.D.

Dean

6/30/16.



SL No: 10268 trate: 29/10/2021 Resset

Sold to Y.V. Anjameyuly 3/0 sectaremaids, Gubur

For Whom Malapet Institute of Pharmacutical Sciences

For Whom Malapet Togethute of Pharmacutical Sciences

66AA 887674

KONDA MOHAN REDDY

LICENCED STAMP VENDOR

L.No: 07-14-010/2014

R.L. No: 07-14-005/2021

D.No: 19-71, TADIKONDA

GUNTUR DL Cell: 9866368173

MEMORANDUM OF UNDERSTANDING

This Binding of Memorandum of Understanding (hereinafter "Memorandum" or "MOU") is dated 17th day of October 2020.

BETWEEN

Open Accelerator Private Limited at Kolhapur, Maharashtra (hereinafter referred to as "FIRST PARTY" which expression shall mean and include its legal heirs, administrators and permitted assigns)

AND

Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh (hereinafter referred to as "SECOND PARTY" which expression shall mean include its legal heirs, administrators and permitted assigns)

WHEREAS:

A: The parties are interested in working together in connection with the purpose of as described in this memorandum

B: This Memorandum sets out initial relationship between the Parties as well as respective rights and responsibilities of each party.

C. Each Party respectively is expected to act in good faith in accordance with the Memorandum.

NOW THEREFORE IN CONSIDERATION OF the premises and the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto covenant and agree as follows:

Recognized as StartUp by Department of Industrial Policy & Promotion, Government of Indus | DIPP43840
6mpirels Diffice | 202, Dwarts Advero, Opp D Y Patil Medical College, Kasaba Bawada, Kolleger Mahassahtra 416 006
6 | mgm/department of Industrial Policy & Contact | 9552208844 | Email | admin@opesindia.com

CIN | U80800PN2019PTC183483 | Centact | 9552208844 | Email | admin@opesindia.com

Chalapathi Institute of Pharmaceutical Sciences

A.) PURPOSE OF MOU:

- The purpose of this MOU is to help create a larger number of student-driven. on campus start-ups that will add to economic and social value.
- This bond of MOU will aid in teaching students and encouraging them to take up entrepreneurship as a preferred career choice.
- It will help in preparing students to successfully launch their StartUps.
- · Developing customized training & mentoring modules for StartUps and engaging them in pre-startup activities.
- It will help in capacity building programmes/activities for faculty as well as trainers.

The following Objectives will be achieved by the MOU:

- To encourage Science and Technology students to choose entrepreneurship as their careers.
- · To motivate students to convert their Innovation/ Ideas and projects into viable Business Model.
- To create a common virtual platform and ask institutions to submit students' projects on this platform to make the project nationwide.
- · To offer students, from rural regions of India, training in business opportunity identification in their local areas.
- To orient students as to how they can conceptualize social business start-ups that will address social issues.
- To provide handholding support to students for launching their StartUp's during the entire course of their study.
- · To equip students with the necessary skills for managing their business enterprise.

B.) RESPONSIBILITIES OF PARTIES:

FIRST PARTY OpEx Accelerator Private Limited shall have following roles and responsibilities

· StartUp Centre will be established by OpEx StartUp Accelerator at the AICTE Approved Technical Institute so as to efficiently run and build StartUp Ecosystem at Institute.

> Chalapathi Institute of Pharmaceutical Sciences (Autonomous)



- Centre will be affiliated with our Accelerator and our associated Incubators.
 This affiliation will assist institute for recognized StartUp Centre. It will also help centre to simplify fundraising from government.
- Industry-Government-Academic Linkages will be created through formation
 of StartUp Centre Advisory Board & Mentoring Board. All the members
 listed in this will act as Mentor for this Centre. Initially faculty and then
 students will be trained and mentored time to time.
- StartUp Event: Execution of Virtual StartUp Event at Campus for maximum students in order to motivate them for entrepreneurship which will be followed by
- Screening of genuinely interested students for StartUp's who have innovation/ Idea for StartUp
- Training Workshop: Execution of Online StartUp Masterclass Training Program to the Participant Students & Faculties in order to learn all the stages of StartUp.
- Faculty Capacity Building Program: An extensive training workshop to train the faculty cum institute level mentors will be executed for selected & institute nominated faculty members
- Execution of Ideathon virtually where Students needs to present their innovation in front of expert jury members
- Execution of One / Two Days Online Pre-Incubation Training Program (Prototype, Market Survey, Customer Feedback, and Business Model Canvas) by Mentors so that they can understand how to build prototype and Business Model for their Innovation.
- Execution of BOOTCAMP where shortlisted 15-20 teams will present their prototype, market survey, customer feedback, and business model canvas to Jury members
- Best 5 Teams will be admitted as Student StartUp for Incubation under your StartUp Centre where they will be provided with Mentoring, handholding and networking to create their scalable and sustainable StartUp inside the campus.
- After the completion of POC (Proof of Concept) StartUp's will be officially launched inside the campus through a StartUp Launchpad Ceremony which will be covered by Media

Digital Marketing Support and Networking Support will be given to these Successful Student StartUp's

RATOR

REATOR

REAT

Chalapathi Institute of Pharmaceutical Sciences

 Co-branding of every single activity of this centre will be done on Social Media, Digital Magazine and Press Media

SECOND PARTY Chalapathi Institute of Pharmaceutical Sciences shall have the following responsibilities:

- To arrange & allot Infrastructure for StartUp Centre: 2000 5000 Sq. Ft.
 Exclusive Area for StartUp Workplace with computer terminals and
 respective equipment's which shall have at least 5 to 6 cubicles. Institute
 shall keep separate funding for internal infrastructure management like
 Computer terminals, furniture in cubicles, Posters, etc.
- To appoint Single Point of Contact Head, Faculty for StartUp & ED Cell; StartUp Cell committee can have 3 members under Head for classified tasks. Institute can decide whether to pay these appointed faculties or not. Payments to these faculties will not be a part of this MoU.
- Institute shall convey all the activities of Party 1 to the students effectively, and ensure its proper execution at the campus.
- Scheduling of all StartUp Centre related activities will be done time to time in mutual coordination.
- Institute shall create, maintain and record all the documentation related as per the regulatory guidelines, Party 1 shall assist Party 2 in this regard time to time for review.
- Visit to nearest Incubation Centre can be planned by Party 1 and shall be arranged by Party 2. This will plan to travel interested faculty members as well as Students to see the operations and management of the respective incubation centre.

C.) PRICING AND ITS TERMS:

As per the MOU, the Party 2 will be charged ₹3,70,000/- for setting up of StartUp Centre and its related Services as mentioned in MOU.

The institutions can opt for payment in 4 instalments.

- Advance amount of ₹ 1,00,000 at the time of signing this MoU
- 2. 2nd Instalment of ₹ 90,000 after 3 months after signing this MoU
- 3. 3rd Instalment of ₹ 90,000 after 6 months after signing this MoU
- 4. 4th Instalment of ₹ 90,000 after 9 months after signing this MoU
- The cost does not include StartUp Masterclass as per the mutual discussion between two parties. Participants can separately pay for this Masterclass if they

- are interested for the same. (Party 1 will give 50 Participant Access of Masterleass for FREE as per quotation)
- All above costs are towards the services and intellectuals from Party 1, hence in any concern if this agreement is cancelled there will not be any refund of the payment paid.

D.) CHANGES TO MEMORANDUM

This Memorandum may be amended at any time by agreement between the Parties. Any changes to this Memorandum must be made in writing and signed by the Parties.

E.) GENERAL OBLIGATIONS

- (a) Notwithstanding the non-binding nature of this Memorandum, the Parties will act in good faith and will use their best endeavors to achieve the Purpose and to give effect to the terms of this Memorandum.
- (b) The Parties hereby acknowledge and agree that they will each respectively perform all acts and execute all documents as reasonably required in order to give effect to the terms of this Memorandum.
- (c) Each Party agrees to cooperate in the spirit of mutual understanding and goodwill in order to develop the Parties' relationships with one another and in order to pursue the Purpose.

F) CONFIDENTIALITY

- (a) The Parties each hereby acknowledge and agree that in connection with this Memorandum, they may have access to information that is confidential and/or commercially valuable to one or more of the other Parties ("Confidential Information").
- (b) The Parties each hereby acknowledge and agree that they may be both the receiving party in relation to some Confidential Information ("Receiving Party"), and the disclosing party in relation to some other Confidential Information ("Disclosing Party"), and that the terms of this Memorandum may apply to a Party as both a Receiving Party and as a Disclosing Party, as the context so provides.

(c) For the purpose of this Memorandum, Confidential Information may include but is not limited to

Chalapathi Institute of Pharmaceutical Sciences

- (I) information of whatever nature relating to the Project or to another Party (whether relating to the Program or otherwise);
- (II) any information derived from any other information which falls within this definition of Confidential Information; and
- (III) any copy of any Confidential Information. but does not include information which: (I) was known or in the possession of the Receiving Party before it was provided to the Receiving Party by the Disclosing Party, provided that it was known or in the possession of the Receiving Party through legal means, and not as a result of any breach of this Memorandum or any other agreement or obligation relating to confidentiality (whether or not the Receiving Party was a party to such other agreement or obligation); (II) is, or becomes, publicly available, through no fault of the Receiving Party; (III) is provided to the Receiving Party without restriction or disclosure by a third party, who did not breach any confidentiality obligations by making such a disclosure; (IV) is provided to the Receiving Party by the Disclosing Party and is marked "Non Confidential"; or (V) is required by law or regulation to be disclosed, but in the event that this exception applies, it applies only to the absolute minimum necessary and provided that the Disclosing Party is first consulted to establish whether and if so how far it is possible to prevent or restrict such enforced disclosure.
- (d) In relation to any Confidential Information:
 - (I) The Receiving Party shall keep the Confidential Information confidential and secret.
 - (II) The Receiving Party shall only use the Confidential Information for the purpose of working in good faith on the Project in accordance with this Memorandum.
 - (III) The Receiving Party shall not release the Confidential Information to any other party, unless that other party is an advisor who is under a duty of confidentiality, is assisting with the Program, and needs to have the Confidential Information in order to assist with the Program.

(e) If there is any doubt as to whether any particular information constitutes Confidential Information, the Receiving Party should presume it is Confidential Information, until the Receiving Party obtains explicit confirmation from the Disclosing Party that it is not Confidential Information.

- (I) information of whatever nature relating to the Project or to another Party (whether relating to the Program or otherwise);
- (II) any information derived from any other information which falls within this definition of Confidential Information; and
- (III) any copy of any Confidential Information. but does not include information which: (I) was known or in the possession of the Receiving Party before it was provided to the Receiving Party by the Disclosing Party, provided that it was known or in the possession of the Receiving Party through legal means, and not as a result of any breach of this Memorandum or any other agreement or obligation relating to confidentiality (whether or not the Receiving Party was a party to such other agreement or obligation); (II) is, or becomes, publicly available, through no fault of the Receiving Party; (III) is provided to the Receiving Party without restriction or disclosure by a third party, who did not breach any confidentiality obligations by making such a disclosure; (IV) is provided to the Receiving Party by the Disclosing Party and is marked "Non Confidential"; or (V) is required by law or regulation to be disclosed, but in the event that this exception applies, it applies only to the absolute minimum necessary and provided that the Disclosing Party is first consulted to establish whether and if so how far it is possible to prevent or restrict such enforced disclosure.

(d) In relation to any Confidential Information:

- (I) The Receiving Party shall keep the Confidential Information confidential and secret.
- (II) The Receiving Party shall only use the Confidential Information for the purpose of working in good faith on the Project in accordance with this Memorandum.
- (III) The Receiving Party shall not release the Confidential Information to any other party, unless that other party is an advisor who is under a duty of confidentiality, is assisting with the Program, and needs to have the Confidential Information in order to assist with the Program.

(e) If there is any doubt as to whether any particular information constitutes Confidential Information, the Receiving Party should presume it is Confidential Information, until the Receiving Party obtains explicit confirmation from the Disclosing Party that it is not Confidential Information.

(f) Each Party's respective obligations of confidentiality under this clause will survive the termination or expiration of this Memorandum and will continue after that Party ceases to participate in the Program

G.) INTELLECTUAL PROPERTY

- (a) In connection with each Party's participation in the Project, each Party respectively may generate, create, contribute to, write or produce intellectual property ("Project Intellectual Property").
- (b) For the purposes of this Memorandum, "Project Intellectual Property" includes but is not limited to:
- (I) information, ideas, innovations, developments, improvements, inventions, discoveries, plans, reports, drawings, specifications, advice, analyses, designs, methodologies, code, artwork, or any other intellectual property; and
- (II) intellectual property that results in any way from work performed for or on behalf of the Project (whether performed by the Party or by somebody else); and
- (III) intellectual property, whether the Party generates, creates, contributes to, writes or produces that intellectual property: (A) directly, indirectly, independently or in cooperation or conjunction with another person or persons; and (B) during the Party's ordinary working hours, or outside of the Party's ordinary working hours; and (C) at the location where the Party ordinarily participates in the Project, or at some other location.
- (IV) intellectual property that results in any way from the use of resources or assets in connection with the Project, including reference or other materials, personnel, facilities, or other resources; and
- (V) intellectual property that relates in any other way to the Project or any business which is developed in connection with the Project.
- (c) Unless otherwise expressly agreed between the Parties, nothing in this Memorandum is intended to create any transfer or assignment of any intellectual property rights in relation to any Project Intellectual Property.
- (d) Unless otherwise expressly agreed between the Parties, in the event that a particular Party generates, creates, contributes to, writes or produces an item of Project Intellectual

Property, that Party shall retain any and all intellectual property rights in relation to that item of Project Intellectual Property.

(e) Each Party's respective obligations under this clause will survive the termination or expiration of this Memorandum and will continue after that Party ceases to participate in the Project.

H.) EXCLUSIVITY

- (a) Each Party (which, for the purpose of this clause is referred to as the "Representing Party") hereby represents to the other Party that:
- (I) Upon the signing of this Memorandum, the Representing Party will terminate any discussions or negotiations with any party other than a Party to this Memorandum ("Third Party"), which relate to the Purpose or to the Program ("Third Party Discussions"), in which the Representing Party, or any employee, agent, advisor, contractor or other representative of the Representing Party, may be engaged.
- (II) While this Memorandum is in effect, the Representing Party will not, directly or indirectly: (A) Engage in any Third Party Discussions; or (B) Invite, encourage, seek or otherwise solicit any Third Party to engage in Third Party Discussions; or (C) Respond to any invitation or solicitation from any Third Party in relation to any Third Party Discussions (except to explicitly reject such invitation or solicitation); or (D) Enter into any agreement, memorandum of understanding, heads of agreement, letter of intent, or other arrangement with any Third Party in relation to any Third Party Discussions (whether legally binding or non-binding).
- (III) The Representing Party will ensure that any employee, agent, advisor, contractor or other representative of the Representing Party also complies with the obligations under this clause.
- (b) For the sake of clarity, "Third Party Discussions" do not include discussions or negotiations in which the Representing Party may engage with any Third Party in order to pursue the Purpose in good faith and in the spirit of this Memorandum.

I.) DURATION OF MOU

(a) This Memorandum will commence on 17/10/202 and will remain valid for 1 year. Thereafter, the agreement can be renewed with mutual consultation between the Parties.

WERATOR OF THE PARTY OF CONTROL O

- (b) The Parties will negotiate in good faith in order to sign a final and legally binding agreement in relation to the Project (the "Agreement") on or before 17-10-2020
- (c) This Memorandum will remain in effect until the Agreement commences, or unless and until otherwise terminated by the Parties.
- (d) The Parties may terminate this Memorandum by mutual agreement.
- (e) Either Party may terminate this Memorandum forthwith by providing immediate notice in writing to the other Party.

J.) INDEMNITY

Each Party ("Indemnifying Party") hereby agrees to indemnify and hold the other Party harmless from all damages, costs, attorney's fees or other losses arising out of or relating to:

- (a) breach of this MOU by the Indemnifying Party;
- (b) breach of any representation or warranty by the Indemnifying Party.

K.) SEVERABILITY

If any provision of this MOU shall for any reason be held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision thereof, and this MOU shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. Any invalid or unenforceable provision of this MOU shall be replaced with a provision that is valid and enforceable and most nearly gives effect to the original intent of the invalid / unenforceable provision.

L.) ENTIRE AGREEMENT

This MOU constitutes the entire agreement and understanding of the Parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements, understandings duties or obligations between the Parties with respect to the subject matter hereof.

M.) NO OTHER RIGHTS GRANTED

Nothing in this MOU is intended to grant any rights under any patent, copyright or other intellectual property rights of any Party in favor of the other, nor shall this MOU be construed to grant any Party any rights in or to the other Party's Confidential Information, except the limited right to use such Confidential Information in connection with the Project under this MOU

N.) AMENDMENTS

Any change, alteration, amendment, or modification to this MOU must be in writing and signed by authorized representatives of both the Parties.

O) DISPUTE RESOLUTION

- (a) Any dispute(s) arising out of this MOU shall, as far as possible, be settled amicably between the Parties hereto failing which the following shall apply:
- (b) The courts at Kolhapur shall have exclusive jurisdiction over any dispute, differences or claims arising out of this MOU.
- (c) If either Party employs attorneys to enforce any rights arising out of or relating to this MOU, the prevailing Party shall be entitled to recover reasonable costs and attorneys' fees.

P.) GOVERNING LAW

This MOU and all issues arising out of the same shall be construed in accordance with the laws of India.



SIGNED BY THE PARTIES ON 17TH DAY OF OCTOBER 2020 AT RESPECTIVE OFFICES WITH VIRTUAL MOU SIGNING CEREMONY

Sachin Kumbhoje
Director & CEO,
OpEx Accelerator P Ltd

Anjori Kumbhoje
Director, OpEx Accelerator P Ltd

Pooja Paragori
HR & Admin, OpEx Accelerator Ltd

Prof. Rama Rao Nadendia Serices
Principal, Chalapathi Institute of
Pharmaceutical Sciences
Pharmaceutical Sciences

Pharmaceutical Sciences

Principal, Chalapathi Institute of
Pharmaceutical Sciences
Pharmaceutical Sciences

Seal of Party 1

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34.

Seal of Party 2



s.No: 48 93 pt. 15 p ? 2020 Rs. 10 _____ ANDHRA PRADESH

Sibar Institute of Dental Sciences, Guntur Rep by

Dr.Lingamneni Krishna Prasad S/o Dr.L.Subba Rao, Vijayawada

91AA 940964

LICENCED STAMP VENDOR

L.No: 07-010-002/2012 RL.No: 07-10-010/2018 PONNUR. Cell: 9848019602

MEMORANDUM OF UNDERSTANDING (MOU)

This Memorandum of Understanding is entered into and executed on this the 28th day of October 2020 by and among:

M/s. SIBAR Institute of Dental Sciences, Takkellapadu, Guntur – 522509, Andhra Pradesh; represented by it's Dean Dr. LINGAMANENI KRISHNA PRASAD.

[HEREINAFTER to be referred to as "SIDS" of First Party)

AND

For Whom

Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, LAM, Guntur – 522034, Andhra Pradesh; represented by it's Principal – PROF. RAMA RAO NADENDLA.

(HEREINAFTER to be referred to as "CLPT" of Second Party)

Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34,

Page 1 of 3

The first party has approached the second party for utilizing the facilities offered by the Institute, for understanding and conducting research related activities.

The Dean, Sibar Institute of Dental Sciences and the Principal, Chalapathi Institute of Pharmaceutical Sciences are to mutually coordinate and oversee the implementation of this agreement.

NOW THE MEMORANDUM OF UNDERSTANDING WITNESSETH AS UNDER:

- A joint committee comprising of designated staff members from both parties explores newer opportunities for further research in the field of Dental sciences and associated Medical subjects. The joint committee also decides regarding streaming of funds for the research projects with the consent of both parties.
- The First party agrees to provide access to Chalapathi Institute of Pharmaceutical Sciences, Guntur, for the use of required samples with all relevant details.
- Chalapathi Institute of Pharmaceutical Sciences, Guntur, will use all the samples and relevant information provided by the First party for conducting research only in the concerned departments of the Second party, based on the type of research being conducted.
- The information about samples and the results are the property of both the parties.
- The information about the samples and the results are not allowed to be transferred to any other party without the consent of the First party.
- All credentials arising out of the research work undertaken under this MOU
 are to be appropriately shared by both the institutes as decided by the joint
 committee.
- 7. The expenditure incurred for all post-graduate projects will be borne by the first party (Sibar Institute of Dental Sciences). The second party (Chalapathi Institute of Pharmaceutical Sciences, Guntur) should allow the students to work in the laboratory only with the permission letter issued by Dean of the first party.
- 8. Both the parties can extend the period of MOU upon mutually agreed terms and conditions.
- Individual projects taken up by either party, which do not involve the utilization/mutual exchange of facilities of other party as in this MOU, do not need the consent of the other party.
- The First party is permitted to access all the details on the progress of the study, data and results on the joint studies or projects undertaken under this venture.
- The Second party shall submit a progress report at periodical intervals i.e. once in three months to First party.
- 12. Both the parties will put all efforts inviting grants for various research projects from funding sources.

13. The MOU is for a period of five years from the date of signing and can be renewed with mutual consent.

IN WITNESSETH where the parties herein above have signed and executed the above MOU on the Day 28th Month October Year 2020, herein above mentioned, in presence of the following witnesses...

FIRST PARTY

(Dr. L. Krishna Prasad)
Dean,
Sibar Institute of Dental Sciences,
Takkellapadu, Guntur,
Andhra Pradesh.

DEAN
DEAN
DEAN
BAR INSTITUTE OF DENTAL SCIENCES
GUNTUR-522509, A.P., India.



SECOND PARTY

(Prof. Rama Rao Nadendla)
Principal & Dean,
Chalapathi Institute of Pharmaceutical
Sciences, Chalapathi Nagar, LAM,
Guntur – 522034, Andhra Pradesh.

PRINCIPAL
Chalapathi Institute of Pharmaceutical Sciences
(Autonomous)
Chalapathi Nagar, LAM, GUNTUR-34

WITNESSES:

28/10/20

(Dr. B.V. Ramana Reddy)
Professor & Head
Department of Oral Pathology
Sibar Institute of Dental Sciences,
Guntur.

De B.V. BAMANA REDOY
Prof. & Head
Dopt. of One Publishing
sear inclinate of period. Manage
QUNTUR-622 888.

Mr. P. Prachet

(Mr. P. Prachet)
Assistant Professor,
Pharmaceutical Analysis,
Chalapathi Institute of Pharmaceutical
Sciences, Chalapathi Nagar, LAM,
Guntur – 522034, Andhra Pradesh.



မ ျှော်ညိုင်နီ आंध्र प्रदेश ANDHRA PRADESH Sold to Y. V. Anjanegula e/o Sectatamaiah, Gutur.

Sold to Y. V. Anjanegula e/o Sectatamaiah, Gutur.

For Whom Chalapathi Institute of Pharmacutical Sciences.

Lam, Gutur

Wham & CONDA MOHAN REDDY LICENCED STAMP VENDOR L.No:,07-14-010/2014 R.L. No: 07-14-005/2021 D.No: 19-71, TADIKONDA GUNTUR Dt. Cell: 9866368173

ISTITUTION MEMORANDUM OF UNDERSANDING BETWEEN

FOR COLLOBORATION OF ACADEMIC/CLINICAL/RESEARCH INTERACTION

In accordance with the mutual desire to promote cooperation between Spartan Health Sciences University School of Medicine, St.Lucia, West Indies and Chalapathi Institute of Pharmaceutical Sciences, Lam, Guntur both the University and Institution enter into this formal statement of collaboration in the form of Memorandum of Understanding (MOU) for the purpose of the form of Memorandum of Unders Academic/Clinical/Research interaction.

Both the institutions have found it mutually beneficial to explore cooperative activities for the following purposes:

- Training of M.D./B.Pharmacy / Pharm-D / M.Pharmacy students at Spartan Health Sciences University School of Medicine, St.Lucia, We Spartan Health Sciences University School of Medicine, St. Lucia, Indies and Chalapathi Institute of Pharmaceutical Sciences, Lam,
- 2. Collaboration in Academic/Clinical/Research activities between and ichool of Medicine, St.Lucia, dies and Chalapathi Institute of Pharmaceutical Sciences
- Exchange of visits between Chalapathi Institute of Pharmaceutical Sciences.

 Exchange of visits between Chalapathi Institute of Pharmaceutical Sciences, Professionals/faculty members and Students of Spartan Health Sciences University School of Medicine to their counter part and place.

 Organization of joint Seminars/Training programs/Meetings.

 Extra Mural Research facility to the faculty members of Spartan Health Sciences University School of Medicine, St. Lucia, West Indies and Chalapathi Institute of Pharmaceutical Sciences Counter
- Chalapathi Institute of Pharmaceutical Sciences, Guntur

It is understood that the details of joint activities/conditions for utilization of results achieved, arrangements for specific visits, exchange and all other form of cooperation will be handled on mutually agreeable terms for each specific case.

With Charles 14.12.08 PRINCIPAL - Wholeyn President Chalapathi Educational Society path Institute of Pharmaceu Spatial Treatth Science (Autonomous) School of Medicine St. Lucia, West Indies.